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Abstract 
Axonal loss is the main determinant of permanent neurological disability in the 
demyelinating disease, multiple sclerosis. However, there remains uncertainty 
regarding the nature of the cellular factors that elicit axonal injury. Using a non-
immune mediated model of demyelination, the Plp1-overexpressing mouse (line 
#72), it has been shown that early axonal changes occur most frequently in 
regions of active demyelination where microglia/macrophages are phagocytosing 
myelin debris (Edgar et al.2010). With this in mind, it seems reasonable to 
hypothesise that myelin-laden microglia/macrophages are axono-toxic. 
However, the literature is contradictory, with both pro- (Williams et al., 
1994;Mosley and Cuzner, 1996;van der Laan et al., 1996) and anti-inflammatory 
(Boven et al., 2006;Liu et al., 2006) properties having been ascribed to this 
population.  The aims of this study were therefore to determine, using an in 
vitro myelinating culture system as a model of CNS white matter, whether 
myelin-laden microglia/macrophages acquire a (i) pro-inflammatory/axono-toxic 
or (ii) anti-inflammatory/axono-protective phenotype.  
Myelinating cultures were prepared from embryonic mice expressing cyan 
fluorescent protein under the Thy1 promoter, rendering a subset of neurons 
fluorescent. Myelin-enriched tissue fractions, to mimic myelin debris, were 
prepared from wild type or Plp1-overexpressing adult mouse spinal cord and 
labelled with a rhodamine antibody labelling kit.  Myelin fractions were added 
directly to myelinating cultures at 20, 24 or 27 days in vitro (DIV), for 7, 3 or 1 
day(s), respectively. Rhodamine-labelled myelin was phagocytosed by CD45  
positive microglia/macrophages within 24 hours of its addition to the cell 
cultures.  The phagocytosis of myelin had no effect on CD45 positive cell 
density, size or morphology, even after incubation for up to 7 days. Densities of 
CFP-positive neurites were quantified and the proportion of CFP-positive 
neurites manifesting signs of injury were calculated. There was no evidence that 
myelin-laden microglia/macrophages could elicit axonal injury in vitro, with no 
changes in neuritic density or integrity observed in myelin treated cultures 
compared to controls. To determine if myelin-laden cells exert an anti-
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inflammatory, axono-protective effect in an inflammatory environment, cultures 
were treated with 100 ng/ml lipopolysaccharide (LPS). Pro-inflammatory 
cytokines, such as IL-1α, IL-1β, IL-6 and TNF-α were up-regulated in the medium 
from the LPS-stimulated cultures. However, these levels were not altered when 
cultures were pre-treated with myelin debris, to generate myelin-laden 
microglia. In these LPS-stimulated cultures, neuritic densities and neuritic 
integrity remained unaltered, either in the presence or absence of myelin-laden 
microglia/macrophages, compared to controls. Therefore the putative axono-
protective effect of these cells could not be determined.   
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1 Introduction 
1.1 Overview of the mammalian central nervous system 
The mammalian nervous system comprises the peripheral nervous system (PNS) 
and the central nervous system (CNS). The CNS consists of the brain and spinal 
cord, which are themselves comprised of grey matter and white matter. Grey 
matter contains neurons and glia; white matter contains glial cells and 
myelinated and non-myelinated axons that extend from neuronal cell bodies in 
the grey matter. Both grey and white matter contain a rich network of blood 
vessels. 
1.1.1 Neurons  
Neurons are highly specialised cells that constitute around 10 percent of total 
CNS cells. They comprise a cell body (perikaryon) containing a nucleus and 
surrounding cytoplasm, axon and several dendritic processes which extend from 
the cell body and branch multiple times. Most neurons have only a single long 
axonal projection, but some have multiple axonal projections. Neurons are 
electrically excitable cells, capable of transmitting information by means of 
electrical impulses.  The dendritic processes are responsible for receiving stimuli 
from adjacent neurons or receptor organs. The information then passes from the 
neuronal cell body along the axon to the synaptic terminal.  The information is 
then transmitted to dendrites of another neuronal cell or, in the PNS, to an 
effector organ (reviewed in (Edgar and Griffiths, 2009)).          
1.1.2 Axons  
Axons are the main transmission lines of the nervous system.  Axons may extend 
over very long distances. For example, in man, some axons extend for a meter or 
more from the cell body. The axonal diameter is much smaller than that of the 
neuronal cell body. Axons range in diameter from  between <0.3 and >10 
Chapter 1  22 
micrometers in humans (Graf and Schramm, 1984). However, for each axon, the 
diameter remains relatively constant throughout its length (Friede and 
Samorajski, 1970).  
The axonal cytoskeleton comprises actin filaments and a network of 
neurofilaments and microtubules, which are arranged parallel to the length of 
the axon.  Neurofilaments provide structure to the axon and are the main 
determinant of axonal diameter (Cleveland et al., 1991;Hoffman et al., 1984). 
Microtubules provide the main ‘tracks’ for transportation upon which motor 
proteins, such as kinesin and dynein, carry organelles such as mitochondria, 
lysosomes and vesicles and also cytoskeletal polymers, in anterograde and 
retrograde directions.  
Axonal transport occurs throughout the life of the axon and is essential for 
axonal growth and maintenance.  The rates at which cargoes are transported 
along the axon are defined as fast or slow (Brown, 2003). For example, fast 
transport  traffics membranous organelles containing proteins, lipids and 
polysaccharides required for general axonal integrity, and mitochondria which 
are targeted to sites of metabolic demand (Morris and Hollenbeck, 1993). The 
transport of cytoskeletal proteins such as actin and tubulin, occurs at a much 
slower rate and the delivery of these proteins is required for cytoskeletal 
maintenance and long range remodelling during axonal outgrowth (Brown, 2003). 
Since axonal integrity relies on the axonal transport of vital molecules and 
organelles, interruption to this transport system, by acute axonal injury or as a 
consequence of a genetic abnormality, may eventually result in axonal 
degeneration (reviewed in (Edgar and Nave, 2009)).   
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1.1.3 CNS glial cells 
1.1.3.1 Oligodendrocytes 
The majority of CNS axons are ensheathed in a lipid-rich myelin membrane that 
is produced by oligodendrocytes. The relationship between the oligodendrocyte 
and the axon is a complex and reciprocally dependant one. The axon has a 
crucial influence on both the differentiation and survival of the oligodendrocyte 
during development, while the oligodendrocyte maintains long term integrity of 
the myelinated axon (Nave, 2010;Edgar and Nave, 2009) and shapes the axon 
during its development (Nave, 2010;Edgar and Nave, 2009). However, the 
maintenance of the myelin sheath also depends on the health of the axon.  For 
example axonal degeneration or transaction leads to myelin breakdown 
(reviewed in Edgar and Griffiths 2009). 
 A single oligodendrocyte is capable of myelinating several axonal segments 
simultaneously. As oligodendroglia mature, they form elaborate sheet-like 
projections that are extensions of their plasma membrane. Transport of myelin 
proteins or their mRNAs, for example myelin basic protein (MBP), proteolipid 
protein (PLP) and its isofom DM20, and 2',3'-cyclic-nucleotide 3'- 
phosphodiesterase (CNP) are transported from the oligodendrocyte cell body to 
the myelin membrane during myelination.  Although not fully understood, the 
sequence of events that culminate in myelination ensues when the 
oligodendrocyte process comes into contact with the axonal membrane. The 
process then begins to spirally wrap around the axon several times, expelling 
cytoplasm to form dense layers of compact myelin. The cytoplasm filled channel 
that remains around the periphery of the oligodendrocyte process forms the 
inner and outer non-compact tongues and the paranodal loops.  
The myelin sheath is not continuous along the length of the axon. It is 
interrupted at regular intervals by small amyelinated regions, approximately one 
micrometre long, called nodes of Ranvier that facilitate saltatory conduction of 
electrical impulses.The main purpose of myelin is to increase the speed at which 
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impulses propagate along the nerve fibres from the neuronal cell body to the 
axon terminus.  
1.1.3.2 Astrocytes   
The other CNS macroglial cell is the astrocyte. Astrocytes perform many 
functions including maintaining normal levels of extracellular ion concentration 
during neuronal activity and providing biochemical support to epithelial cells 
that form the blood brain barrier. They have also been shown to have a role in 
repair and in scar formation within the CNS following traumatic injury (Renault-
Mihara et al., 2008;Nash et al., 2011). 
1.1.3.3 Microglia 
Microglia, unlike oligodendrocytes and astrocytes, derive from mesenchymal 
tissue rather than from neuroepithelium, and account for around 10-15 percent 
of all CNS glial cells  (Rock et al., 2004).  However the true origin of microglia 
remains controversial (Prinz et al., 2011). It was previously assumed that 
embryonic and postnatal myeloid progenitors, derived from the bone marrow, 
contributed the majority of microglia of the brain. However more recent studies 
(Ginhoux et al., 2010) investigating the origin of microglia in mice, found that 
embryonic macrophages from the yolk sac were responsible for almost the entire 
population of adult microglia in the brain, with peripheral myeloid cells 
contributing minimally (Ginhoux et al., 2010;Prinz et al., 2011). Such recent 
studies also suggest that resident microglia are functionally distinct from other 
bone marrow or blood derived monocytes that may enter the CNS as a result of 
systemic inflammation or injury (Prinz et al., 2011). 
Microglia perform many essential functions including scavenging, antigen 
presentation and phagocytosis, the last of which is the main focus of this thesis. 
Microglia cells become activated upon CNS insult, encouraging circulating 
monocyte recruitment and causing localised inflammation.  Microglia can be 
identified using a variety of antibodies. For example, antibodies to cluster of 
differention factor 45 (CD45) or CD11b (Mac 1) recognise molecules that reside 
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on the cells’ surface. Antibodies to CD68 recognise a specific antigen in the 
lysosomal membrane of phagocytes that is upregulated during phagocytotic 
activity (Bauer et al., 1994). Although it is possible to differentiate between 
macrophages and monocytes using antibodies against surface antigens such as 
DC11b and CD45, in the CNS, endogenous microglia and recruited macrophages 
are indistinguishable.  
 
1.2 The immune system 
1.2.1 The innate immune system of the CNS 
Microglia are the resident macrophages of the CNS and are part of the innate 
immune system. As mentioned previously, one of their main roles is to scavenge 
and breakdown debris by phagocytosis. Phagocytosis is one of the first 
mechanisms of defence against invading micro-organisms and is also important in 
the removal of damaged tissue or senescent cells (Magnus et al., 2001). For 
example, in areas of active demyelination, microglia (probably in combination 
with infiltrating macrophages) must remove large volumes of myelin debris.  
During this process microglia become 'activated', undergoing morphological 
changes and an upregulation in expression levels of major histocompatibility 
complex (MHC) class II (Beyer et al., 2000). For example, in enriched microglial 
cultures exposed to membranes of either neuronal or glial origin, there is a 
notable increase in expression of MHC class II (Beyer et al., 2000). Morphometric 
analyses of the same cultures showed that the cells also acquire morphological 
changes towards an amoeboid appearance, compared to non-treated controls. 
Interestingly, similar morphological changes were observed in microglia exposed 
only to latex beads (Beyer et al., 2000), indicating that phagocytosis per se, is 
sufficient to induce such changes. However, although there was an obvious 
change in appearance in response to the phagocytosis of beads, there was no 
enhanced MHC class II expression, which was in contrast to their membrane 
exposed counterparts (Beyer et al., 2000). This suggests that there are different 
degrees of activation of phagocytic microglia/macrophage (Beyer et al., 2000). 
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Although morphological and biochemical changes associated with phagocytic 
activity have been documented (Perry, 1994;Ransohoff and Perry, 2009;Polazzi 
and Monti, 2010), the issue surrounding the effect that this has on the cells’ 
phenotype is a matter of debate with both pro- (van der Laan et al., 1996;Mosley 
and Cuzner, 1996;Williams et al., 1994) and anti-inflammatory (Boven et al., 
2006) phenotypes having been described (see Section 1.4).  
 
1.2.2 The adaptive immune system 
The adaptive immune system comprises, among other cells, B- and T-
lymphocytes. B- and T-cells as well as natural killer (NK) cells are derived from 
the same multipotent hematopoietic stem cells, and are morphologically 
indistinguishable from one another until after they are activated (Janeway C.A. 
et al., 2005). There are a number of subgroups of T-cells including cytotoxic T-cells 
(CD8 +ve cells), which are responsible for inducing cell death of infected, damaged or 
dysfunctional cells and T-helper cells (CD4 +ve cells), which can be further subdivided 
into Th1,  Th2 , Th17 and T-regulatory cells. B-cells are the major cells involved in 
the production of antibodies that circulate in blood plasma.  The main 
difference between B-cells and T-cells is how they recognise antigen.  T-cells 
recognise an antigen in its processed form, for example, as a peptide expressed 
by an MHC molecule (explained below), while a B-cell is capable of recognising 
an antigen in its native form. 
After a single encounter with a specific pathogen, the cells of the adaptive 
immune system, in particular memory T-cells, have the ability to recognise the 
same pathogen in order to mount increasingly strong attacks each time the 
pathogen is encountered. The system is very adaptive in order to generate the 
diversity in the native immune repertoire. This is due to a method of somatic 
hypermutation (a process of accelerated somatic mutations) that allows a small 
number of genes to generate a number of different antigen receptors, which are 
then uniquely expressed on each individual lymphocyte. Due to these small 
irreversible changes in each cell’s DNA, all the progeny of that cell will inherit 
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the genes encoding that same specific receptor repertoire, providing the key to 
long-lived immunity.   
1.2.3 Interaction between cells of the adaptive and innate immune 
systems 
Interaction between these two systems is controlled by a complex 
cytokine/chemokine network and expression of cellular surface antigens. MHC 
molecules are found in all nucleic cells and are involved in regulating immune 
responses. Protein molecules, either the host’s own or invading entities, are 
degraded within a cell and then epitopes of these proteins are displayed on the 
cell surface by MHC molecules and presented to resident immune cells. By 
themselves, naive T-cells are unable to recognise foreign antigens unless they 
have been processed by an antigen presenting cell (APC) and expressed via the 
MHC molecules on the APC’s surface. There are two types of MHC molecules, 
class I and class II. Most cells in the body are capable of presenting foreign 
peptides to cytotoxic T-cells through MHC class I molecules and therefore act as 
APCs. MHC class II molecules are present on certain immune cells themselves, 
for example dendritic cells and microglia/macrophages, which are also known as 
professional APCs.  These professional APCs are very efficient at internalising 
invading entities, either by phagocytosis or by receptor-mediated endocytosis 
and then displaying the foreign peptides through MHC class II. Once the APCs 
have internalised the invading entity, they migrate to lymph nodes where they 
present the foreign peptides to neighbouring T-cells which can recognise them as 
being foreign. Subsequently, the presenting cell and all others displaying a 
similar protein can be destroyed.    
1.3 Axonal injury in myelin disorders 
Axonal injury is an integral part of a number of myelin disorders, with axonal 
loss contributing to the irreversible disease progression and clinical disability 
(Bjartmar et al., 1999). Such myelin disorders include multiple sclerosis (MS) 
(see 1.3.1) in which there exists a strong correlation between inflammatory 
demyelination and axonal transection (Trapp et al., 1998a), and the 
leukodystrophies such as Pelizaeus-Merzbacher disease (PMD) and their mouse 
models (see 1.3.2), in which a secondary inflammatory response at sites of 
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active demyelination is associated with acute axonal injury (Edgar et al., 
2010;Garbern et al., 2002b) 
1.3.1 Multiple sclerosis 
MS is a prevalent neurological disease that affects over 100, 000 people in the 
UK alone (Multiple Sclerosis Society.org, 2012). It is thought to be an autoimmue 
mediated disorder, in which the body’s own immune cells inappropriately 
recognise proteins on the myelin surface as foreign. It is a very variable and 
complex disease associated with the breakdown of the myelin sheath 
(demyelination). Although MS is classically considered an inflammatory 
demyelinating disease it is now recognised that axonal loss is the main cause of 
permanent neurological disability (Ferguson et al., 1997;Trapp et al., 1998b;De 
Stefano et al., 1998). 
MS follows various courses; relapse/remitting, primary progressive and 
secondary progressive.  The factors that contribute to axonal damage in MS and 
other demyelinating diseases are still uncertain. However, there is evidence to 
suggest that activated immune system cells, including T and B lymphocytes, 
macrophages and microglia, can harm axons (Edgar et al., 2010;Rasmussen et 
al., 2007;Hendriks et al., 2005) (Sobottka et al., 2009;Howe et al., 2007).  
 
1.3.2 Pelizaeus-Merzbacher disease and the Plp1 overexpressing 
mouse model  
Pelizaeus-Merzbacher disease (PMD) is classically considered a dysmyelinating 
disorder, in which myelin formation is perturbed. Many mutations in the PLP1 
gene have been identified in man and give rise to a broad spectrum of disease 
severity. The many mutations include point mutations and splice mutations, 
however, duplication of the PLP1 gene is the most common cause of PMD, as 
reviewed by (Yool et al., 2000). PMD is not classically considered an 
inflammatory disorder, however low grade inflammation has been observed in 
Plp1 over expressing models mouse models (Ip et al., 2006;Edgar et al., 2010).  
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Axonal degeneration in PMD has been reported (Shy et al., 2003;Garbern et al., 
2002a).  
The proteolipid protein (Plp1) gene over expressing mouse (line #72; (Readhead 
et al., 1994)) is a model of PMD, due to gene duplication. The homozygous #72 
model has an approximate 2-fold increase in steady state levels of Plp1 mRNA. 
The Plp1 gene encodes proteolipid protein (PLP) and its isoform, DM20. 
PLP/DM20 is one of the key proteins expressed by the oligodendrocyte and is 
located in the compact myelin sheath, where it is involved in stabilizing 
membrane junctions (Klugmann et al., 1997b). PLP/DM20 is also important for 
glial/axonal interactions and axonal survival (Klugmann et al., 1997a;Edgar et 
al., 2002;Griffiths et al., 1998).  
The homozygous Plp1-transgenic mouse forms CNS myelin initially, albeit in 
reduced amounts, but the biochemically abnormal myelin subsequently breaks 
down. Previous studies showed that the pattern of demyelination occurred in a 
rostral to caudal gradient within the optic nerve, producing two distinct regions 
at postnatal day (P)120; a chronic non-inflammatory demyelinated region and an 
active inflammatory, demyelinating region. The region undergoing active 
inflammatory demyelination contained a 10-fold increase in the number of CD45 
positive cells (Edgar et al., 2010). CD45 is a pan-leukocytic marker that marks 
leukocytes including B and T- lymphocytes, macrophages and resident microglia. 
Unlike immune mediated models of demyelination, the breakdown of myelin in 
the #72 mouse occurs in the absence of large numbers of T-cells, which are 
infrequent, or B-cells, which are absent (Edgar et al., 2010). Therefore, the 
CD45 positive cells at the site undergoing active demyelination are likely to be 
resident microglia or invading macrophages.  
In MS lesions, acute axonal damage (probably representing sites of axonal 
transport impairment) is associated with active inflammatory demyelination. 
Previous work using immunohistochemical assessment of amyloid precursor 
protein (APP), a marker for axonal transport impairment, showed an 
accumulation of APP at inflammatory demyelinating regions in MS brain 
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(Ferguson et al., 1997). Interestingly, in the Plp1-transgenic mouse, focal sites 
of axonal transport impairment correlate with active, inflammatory 
demyelination. In the Plp1-transgenic mouse, functional axonal transport was 
assessed using fluorescently labelled cholera toxin B subunit (CtB). On analysis, 
it was observed that there was accumulation of the FITC CtB within focal axonal 
swellings at sites of active, inflammatory demyelination (Edgar et al., 2010). 
This raises the possibility that the phagocytosis of myelin debris, at sites of 
active demyelination by the microglia/macrophages (CD45 positive cells) causes 
them to secrete pro-inflammatory factors that have a direct influence on 
adjacent ‘naked’ axons. This is in line with studies that demonstrate the myelin-
laden macrophages produce pro-inflammatory cytokines (Williams et al., 
1994;Mosley and Cuzner, 1996;van der Laan et al., 1996). This observation forms 
the basis of this MSc project. 
 
 
1.4 Neuroprotective versus neurotoxic microglia 
1.4.1 Different microglia/macrophage phenotypes 
It is now known that in association with disease or injury, microglia/macrophage 
can adopt either a pro- or anti-inflammatory phenotype depending upon cues 
received from their microenvironment (Lawson et al., 1990;Boven et al., 2006). 
Therefore the question of whether microglia/macrophages play a detrimental or 
protective role may differ between neurological disorders and between different 
cellular injuries (Popovich and Longbrake, 2008;Schwartz et al., 2006;Neumann 
et al., 2008). 
Two broad subsets of macrophages have been defined. These are M1, activated 
pro-inflammatory or M2, alternatively activated. The latter express anti-
inflammatory molecules including transforming growth factor beta (TGF-β), IL-1 
receptor antagonist (IL-1ra) and CCL8, the last being a specific marker for 
human alternatively activated macrophages (Boven et al., 2006). There are 
many micro-environmental cues that drive microglia/macrophages towards one 
particular state or another. For example Interferon-gamma (IFN-gamma) or 
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tumor necrosis factor (TNF)-α drives the M1 phenotype and IL-10 or IL-4 drive 
the M2 phenotype (Boven et al., 2006). The effects that myelin debris exerts as 
a micro-environmental cue is still controversial. Studies have shown that 
phagocytosis of myelin drives macrophages towards an M1 phenotype and 
secretion of pro-inflammatory cytokines including TNF-α and free radicals, for 
example nitric oxide (NO) (van der Laan et al., 1996;Mosley and Cuzner, 1996) 
which can be detrimental to other cells of the CNS. For example, secretion of 
TNF-α and NO have previously been shown to cause injury to axons by perturbing 
axonal transport in vitro (Stagi et al., 2005;Stagi et al., 2006;De Vos et al., 
2000), and injuring oligodendrocytes, particularly precursor cells (Pang et al., 
2010) in vitro. However, a recent study by Boven and colleagues showed that 
myeloid cells which had ingested myelin actually adapted an anti-inflammatory 
phenotype and expressed a number of anti-inflammatory surface molecules 
while in the absence of pro-inflammatory cytokines (Boven et al., 2006)  .   
 
1.4.2 Cytotoxic phenotype of microglia/macrophages in dys- or 
demyelinating disorders  
Previous studies have provided evidence that in dys- or demyelinating disorders 
microglia/macrophages can adapt a cytotoxic phenotype with secretion of 
proinflammatory mediators capable of inflicting injury to axons and 
oligodendroglia (for example (Nikic et al., 2011;Howell et al., 2010). In the 
context of MS, it has been demonstrated that CSF derived from MS patients in a 
chronic disease stage, induces axonal damage in primary embryonic rat neuron 
cultures following increased exposure (Alcázar et al., 2000;Hendriks et al., 
2005). This indicates that soluble mediators, which were present in the CSF, 
such as TNF-α, IL-1 and IL-6, secreted during the course of the disease by the 
microglia/infiltrating macrophages, are capable of inducing direct axonal 
damage in vitro.  
In animal models, the cytotoxic effects of microglia was observed, for example, 
in an in vivo study using Long Evans shaker rats (les), in which oligodendroglial 
progenitor cells (OPCs) were the target of microglial-mediated injury. The les 
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rat is a myelin mutant in which the primary genetic defect in the 
oligodendrocyte is associated with progressive microglial activation. In this 
model, microglial activation peaked at postnatal day 30 (P30) when “expression 
of MHC II, mRNAs of inflammatory cytokines, and nitric oxide synthase 
accompanies phagocytosis of myelin debris” (Zhang et al., 2003). Zhang’s study 
showed that injection of neonatal les rat brain derived OPCs into the spinal cord 
of these mutants at peak microglial activation was detrimental to the grafted 
cells. Conversely however, if the OPCs were grafted at P14 when there was only 
partial activation of the microglia or if the rats were pretreated with 
minocycline, there was substantial myelination of the dorsal columns after 
transplantation, suggesting that  partial activation of the microglia facilitated 
myelination (Zhang et al., 2003). ‘Activation’ of microglia was characterised 
initially by “increased cell proliferation, enlarged cell volume and upregulated 
expression of antigen such as complement 3 receptor” (Zhang et al., 2001).  
In a Plp1 transgenic mouse model of Pelizaeus Merzbacher disease (line #66) a 
primary genetic defect in the oligodendrocyte, causes dysmyelination. However, 
it has been demonstrated that subsequent activation of microglia/macrophages 
exacerbate the disease process (Ip et al., 2006). Late onset demyelination and 
axonal injury in the white matter tract of this model is accompanied by an 
elevation in both CD11b positive “macrophage-like” cells and CD8 positive T-
lymphocytes (Ip et al., 2006). Crossbreeding the Plp1-transgenic mouse with a 
mouse deficient in the mature T- and B-lymphocyte recombinant activating 
gene-1 (RAG-1) led to a reduction in the numbers of CD11b positive cells and an 
alleviation of pathological changes, demonstrating that the immune cells 
(including microglia/macrophages) play a pathogenetically relevant role in 
manifestation of the disease (Ip et al., 2006).  
At sites of myelin degeneration in MS brain, microglia/macrophages phagocytose 
myelin debris and take on a ‘foamy’ appearance (Boven et al., 2006). Williams 
and colleagues demonstrated that following myelin phagocytosis, human derived 
microglial in culture, adopt a pro-inflammatory phenotype (Williams et al., 
1994). At the peak of myelin phagocytosis (within 12-24 hours after incubation 
with purified myelin), a peak in recorded oxidative bursts and secretion of pro-
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inflammatory cytokines including IL-1, TNF-α and IL-6, was recorded (Williams et 
al., 1994). Similarly, enriched rat-derived macrophage cultures incubated with 
opsonised rat myelin, up-regulated production of pro-inflammatory soluble 
factors including TNF-α and nitric oxide, after myelin phagocytosis (van der Laan 
et al., 1996;Mosley and Cuzner, 1996).  These soluble factors have been shown 
to be toxic to oligodentrocyte precursor cells (Pang et al., 2010) and elicit 
axonal injury in vitro, in particular by damaging axonal mitochondria (Haider et 
al., 2011) and obstructing axonal transport (Stagi et al., 2005;Stagi et al., 
2006;De Vos et al., 2000), suggesting that myelin-laden microglia/macrophages 
are cytotoxic. 
Together, these data suggest that in the context of a dys- or demyelinating 
environment, endogenous microglia and/or recruited macrophages can exert 
injury to neighbouring cells. 
 
1.4.3 Neuroprotective phenotype of microglia/macrophages in 
dys- and demyelinating disorders 
 
Conversely, myelin-laden macrophages have been shown to secrete anti-
inflammatory factors and possibly to facilitate repair of the injured CNS (Boven 
et al., 2006;Polazzi and Monti, 2010). It has been suggested that the prevention 
of infinite expansion of MS lesions is due to a ‘counter-regulatory mechanism' 
that controls inflammation within the CNS and also promotes tissue repair 
(Boven et al., 2006). These authors showed that foamy macrophages within 
demyelinating MS lesions from post-mortem tissue express various anti-
inflammatory markers and phenotypically resemble M2 macrophages (Boven et 
al., 2006). In line with these observations, it has been demonstrated that the 
uptake of human myelin by purified human-derived macrophages in culture 
causes them to express anti-inflammatory molecules including IL-10 and TGF-β in 
response to a pro-inflammatory stimulus, for example lipopolysaccharide LPS 
(Boven et al., 2006;Polazzi and Monti, 2010).  
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Furthermore, there is increasing evidence that suggests that 
microglia/macrophages actually protect or promote the development and 
survival of neurons and oligodendrocytes. Such studies have shown that 
conditioned media from mouse peritoneal macropahges stimulated with myelin, 
contained factors that were neurotrophic for adult dorsal root ganglion neurons 
(DRG) in vitro (Hikawa and Takenaka, 1996), resulting in both enhanced 
neuronal survival and neurite regeneration. This neurotrophic media was specific 
for myelin, as media taken from macrophages treated with the endotoxin, LPS or 
latex beads failed to produce the same effect (Hikawa and Takenaka, 1996). 
Furthermore, secretion of microglia/macrophage derived molecules such as TNF 
α (Arnett et al., 2001) and induction of MHC-II by TNF-α are important 
modulatory events in remyelination (Arnett et al., 2003) and NO protects against 
apoptotic death of oligodendrocytes (Arnett et al., 2002).  Accordingly, 
depletion of macrophages caused delayed CNS remyelination in a rat model of 
chemically induced demyelination (Kotter et al., 2005). 
Together, these data demonstrate the multiplicity of microglial/macrophage 
phenotypes in the context of myelin abnormalities. 
1.5 Thy1-fluorescent mice as tools to examine axonal 
injury 
The use of transgenic mice in scientific research is ever increasing and several 
strains are available that express fluorescent proteins in specific cell or tissue 
types.  The main focus of this study is to observe what influence phagocytic 
microglia/macrophages have on the integrity of adjacent axons. To answer this 
specific question, myelinating cultures were generated using transgenic mice 
expressing cyan fluorescent protein (CFP) under the Thy1 promoter, in a subset 
of neurons (Feng et al., 2000).  Unlike traditional techniques to observe axonal 
pathology including Haematoxylin and Eosin (H and E) staining, amyloid 
precursor protein (APP) histochemistry and electron microscopy, which carry a 
number of limitations and time constraints, expression of this particular 
fluorescent protein facilitates longitudinal imaging of single axons within culture 
and provides a sensitive marker of axonal injury. In conditions such as MS or in 
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instances of traumatic brain injury, axonal swellings have been shown to 
accumulate APP and axonal organelles (Ferguson et al., 1997;Edgar et al., 
2001;Edgar et al., 2007) suggesting a ‘traffic jam’ effect or breakdown of axonal 
transport.  Other studies using transgenic mice expressing an analogue of CFP 
showed that these fluorescent swellings correlated with most, although not all 
of the APP accumulated swellings (Bridge et al., 2007) showing that such 
fluorescent markers are suitable markers of axonal injury.       
 
 
1.6 Aim 
 
The broad aim of this thesis is to use an in vitro model of myelination to 
determine if and how microglia/macrophages that have phagocytosed myelin 
debris influence axonal integrity.  
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2 Materials and Methods  
 
2.1 Animals 
 
All animal studies were approved by the Ethical Committee of the University of 
Glasgow and licensed by the UK Home Office 
 
2.1.1 Breeding 
2.1.1.1 Mice used for myelinating cell culture 
 
C57BL/6N (Charles River) wild type females were mated with C57BL/6N 
hemizygous Thy1-CFP males (Feng et al., 2000). The resultant embryos were 
wild type or hemizygous at the Thy1-CFP locus. 
 
2.1.1.2  Mice used for myelin fraction preparation  
 
Plp1-transgenic mice (line #72) carry a transgene cassette harbouring three 
copies of the murine Plp1 gene (Readhead et al., 1994). Wild type males and 
females or homozygous Plp1 transgenic males and females, on the C57BL/6N 
background, were mated to produce wild type or homozygous Plp1 transgenic 
offspring, respectively. Adult females, aged between P60 and P120 ± 5 days 
were used for myelin extraction.  
 
2.1.1.3 Genotyping 
 
To identify mice carrying the Plp1 transgene, a small length (approximately 3 
mm) of tail was collected under anaesthesia. This procedure was carried out by 
members of Biological Services. 
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To identify mice carrying the Thy1-CFP transgene (see 2.2.2 below) a small ear 
notch was taken and examined under the fluorescent microscope (Olympus IX70 
microscope) using the green wavelength filter.  
 
2.1.1.4 Preparation of genomic DNA  
 
To obtain genomic DNA for genotyping, the tail samples were lysed in 100 µl of 
50 mM sodium hydroxide (Fisher, Leicestershire) at 95 ºC for 90 minutes (based 
on BioTechniques protocol, published in 2000). The samples were vortexed 
thoroughly to assist cell lysis then neutralised using 10 µl of 1 M Tris (Fisher, 
Leicestershire) pH 5.0.   
 
2.1.1.5 PCR to determine the Plp1 transgene status 
 
One µl of each of the lysed tissue samples, 1 µl of water and 1 µl of purified 
positive and negative control genomic DNAs were each added to 24 µl of 
prepared PCR master mix (12.5 µl REDTaq ReadyMix PCR reaction mix with MgCl2 
(Sigma-Aldrich, Dorset), 0.5 µl forward primer PLP (sequence 5/-
CAGGTGTTGAGTCTGATCTACACAAG-3/, 0.5 µl reverse primer αT7 (sequence 5/-
GCATAATACGACTCACTATAGGGATC-3/) (Readhead et al., 1994), 10.5 µl MilliQ 
water (Millipore, Livingston). PCR was performed on a Biometra UNO-
thermoblock PCR thermocycler. The PCR reactions consisted of an initial 
denaturing step of 94 ºC for 3 minutes, annealing step 58 ºC for 1 minute and an 
elongation step 72 ºC for 2 minutes. This was followed by 35 core cycles of 93 ºC 
for 40 seconds, 58 ºC for 1 minute, 72 ºC for 30 seconds and a final cycle of 40 
seconds at 93 ºC, 1 minute at 58 ºC and 3 minutes at 72 ºC. After the final cycle 
the reaction mix was cooled to 4 ºC. PCR products were then separated using gel 
electrophorisis. A 2.5 % agarose (Gibco, Invitrogen, Paisley) gel, containing 1.25 
x 10-4 mg/ml ethidium bromide, was prepared. The gel was prepared and 
immersed in 1 X Tris acetate ethylene-diamine-tetra-acetate buffer (TAE see 
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Appendix 7.1.1). Ten µl of each PCR reaction product, as well as positive and 
negative controls were run in the gel. Samples were electrophoresed at a 
constant voltage of 70 for approximately 20 minutes.  
Gels were viewed on a Herolab UVT-28M transilluminator to reveal PCR product 
bands and images were captured with a COHU CCD camera system attached to a 
Sony Digital Image printer. The presence of the Plp1 transgene cassette yielded 
a 250 bp fragment. Fragment size was determined by side-by-side comparison 
with a 1 kb DNA ladder (Invitrogen, Paisley) which was run in parallel.  
 
2.2 Myelinating cell culture 
2.2.1 Preparation of Poly-L-Lysine coated coverslips  
 
Using sterile technique, sterilised 13 mm glass coverslips (Fisher Scientific, 
Leicestershire) were carefully immersed in 0.01 % Poly-L-Lysine (PLL) (Sigma-
Aldrich, Dorset) at room temperature for at least one hour, to coat them. For 
the 35 mm glass bottom Petri dishes, containing a single 14 mm coverslip, 
(MatTek corporation, Ashland, USA) used for time-lapse imaging, 500 µl of 0.01 % 
PLL was added directly onto the glass bottom at room temperature and 
incubated for 1 hour. After this time the PLL was aspirated off and the 
coverslips/glass bottom dishes were washed twice in deionised water. Using 
sterile forceps, coverslips were individually placed into 35 mm Nunclon (NUNC) 
(Thermo Scientific, Surrey) Petri dishes (3 coverslips per Petri dish) and allowed 
to dry. Petri dishes were used immediately or repackaged and stored at 4 ºC 
until required. Glass bottom dishes were left to air dry after washing and used 
immediately or repackaged and stored at 4 ºC until required. 
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2.2.2 Myelinating cell culture  
Myelinating cultures (Thomson et al., 2008) were generated from spinal cords of 
embryonic day 13 (E13) mice expressing CFP under the Thy1 promoter. Spinal 
cords were dissected and stripped of their meninges. The cords were then 
chopped into small pieces with a sterile scalpel and incubated at 37 ºC for 20 
minutes in 2-4 ml of Hanks Balanced Salt Solution (HBSS) without Mg2+ and Ca2+ 
(Gibco, Invitrogen, Paisley), containing trypsin (final concentration 0.12 %) and 
type I collagenase (final concentration 0.047 %). The reaction was stopped using 
soybean trypsin inhibitor and DNAase (SD solution, see appendix 7.2.1). Cells 
were than dissociated gently four times through a 21 gauge needle and twice 
through a 23 gauge needle to produce a homogenous single cell suspension. The 
cells were then centrifuged in 5 ml plating medium (DMEM 50 %, HBSS 25 % and 
horse serum25%, see Appendix 7.2.2) on a WIFUG lab centrifuge at 800 rpm for 5 
minutes. The supernatant was removed and the remaining pellet resuspended in 
~0.33 ml plating medium per spinal cord. Twenty µl of the cell suspension was 
then mixed with 20 µl of trypan blue and the trypan blue negative cells counted 
on a haemocytometer. Cells were then plated on poly-L-lysine coated coverslips 
(see 2.2.1) at a density of 150,000 cells/cover slip in 100 µl of medium. Each 35 
mm diameter Nunclon dish (Thermo Scientific, Surrey) contained 3 coverslips. 
Two hours after the cells were plated; another 150 µl of plating medium was 
applied to each NUNC dish and uniformly spread using a fine tip artist brush 
which had been UV light sterilised. One hour after the addition of the extra 
plating medium, 500 µl of differentiation medium (DMEM plus glucose and 
hormones, see Appendix 7.2.3) was added. Cells were cultured in differentiation 
medium until 12 days in vitro (DIV) and then in differentiation media minus 
insulin until 28 (± 1) DIV.  
 
2.3 Tissue Preparation 
2.3.1 Tissue collection and fixation 
For immunohistochemical analysis of intact E13 mouse spinal cords, three cords 
from littermates of embryos used for the myelinating cultures were stripped of 
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their meninges and immediately immersed in periodate-lysine-paraformaldehyde 
fixative (P-L-P fixative see Appendix 7.3.1). After two hours at room 
temperature, they were transferred to a solution of 20 % sucrose in PBS and 
incubated overnight for cryoprotection.  
 
 
 
 
 
 
2.3.2 Preparation of APES (3(aminopropyl)triethoxysilane) coated 
slides 
 
For APES (3(aminopropyl)triethoxysilane) (Sigma-Aldrich) coating,  glass 
microscope slides were soaked overnight in 5 % Decon 90 (Decon Lab Ltd), rinsed 
in running distilled water for at least two hours and then oven dried at  70 °C 
The slides were then dipped for 1 minute in methylated spirit, then for 2 
minutes in 0.25 % APES/methylated spirit, rinsed in distilled water, oven dried 
again at 70 °C, then wrapped in foil and stored at room temperature.  
 
 
2.3.3 Cryopreservation and sectioning 
 
The P-L-P fixed and sucrose saturated E13 spinal cords were cut transversely to 
produce rostral and caudal blocks which were then suspended in Tissue-Tec 
O.C.T compound (Miles Laboratories Inc.) in tin foil moulds. The tissue was fast 
frozen in isopentane (Fisher, Leicestershire) cooled in liquid nitrogen. The 
frozen blocks were wrapped in NescoFilm (Bando Chemical Ind. Ltd.) and stored 
at -20 ºC until required. 10 µm thick sections were cut from both regions of the 
cord using an OFT cryostat (Bright Instrument Company, Huntingdon, 
Cambridgeshire) and mounted onto APES-coated microscope slides, air dried for 
1 hour and stored at -20 ºC until required.  
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2.3.4 Immunohistochemistry 
 
The frozen E13 spinal cord cryostat tissue sections were allowed time to come to 
room temperature before being washed in PBS for 10 minutes to remove 
surrounding Tissue-Tec. The sections were then immersed in -20 ºC methanol for 
10 minutes to permeabilise for intracellular or membrane antibody labelling. 
Once permeabilised, the sections were washed in PBS for a further 3 x 10 
minutes. Sections were then immersed in 10 % normal goat serum (NGS) (Sigma-
Alderich, Dorset)  for one hour to block non-specific binding sites before being 
incubated in primary antibody diluted in 10 % NGS overnight at 4 ºC. The next 
day, the sections were washed again in PBS for 3 x 10 minutes and incubated in 
secondary antibody conjugated with fluorescein isothiocyanate (FITC) (Southern 
Biotech, Burmingham), diluted in 10 % NGS for one hour at room temperature. 
After incubation with the secondary antibody, the sections were washed in PBS 
as before. 0.83 µg/ml -1 4,6-diamidino-2-phenylindole (DAPI), a nuclear marker, 
was applied to the sections for 60 seconds. This was followed by another brief 
wash in PBS prior to mounting the sections in antifade mounting medium 
(Citifluor, London). Sections were then examined by epifluorescence using an 
Olympus IX70 microscope and images were captured using a CCD camera system 
(Photonic Science Colour Coolview) and ImagePro 6.0 software (Media 
Cybernatics, Wokingham, Berkshire). FITC absorbs light with a wavelength of 495 
nm and emits light at a wavelength of 525 nm, which is visualised as a green 
light using a blue filter. 
The primary antibodies used for immunohistochemistry were commercially 
available and their source and dilutions are illustrated in Table 1. Anti-CD45, a 
pan-leukocytic marker was used to recognise leukocytes including 
microglia/macrophages. Anti-CD11B and anti-CD68 were used as macrophage 
specific markers. Secondary antibodies used were all raised in goat and their 
source and dilutions are illustrated in Table 2.  
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Table 1. Immunohistochemistry primary antibodies 
 
Primary antibody Isotype Dilution Source 
CD45 Rat IgG  1:300 AbD Serotec, 
Kidlington 
CD11B conjugated 
FITC 
Rat IgG 1:20 BioLegend UK 
Ltd., Cambridge 
CD68 Rat IgG 1:200 Abcam, 
Cambridge 
 
 
 
 
 
 
Table 2. Immunohistochemistry secondary antibodies 
 
Secondary antibody Dilution Source 
Rat Alexa Fluor 488 1:1000 Invitrogen, Paisley 
 
 
 
 
2.4 Myelin isolation 
Sterile myelin was isolated from spinal cords of adult (postnatal day 60-120 (P60-
P120)) wild type and homozygous Plp1-transgenic mice by the technique based 
on the method of (Norton and Poduslo, 1973). Cords were rapidly removed from 
the spinal enclosure by introducing sterile saline under pressure to the lumbar 
spinal column using an 18 gauge hypodermic needle. Cords were ejected through 
the cervical column, which had been severed just below the base of the skull. 
The cords were placed in cryotubes, snap frozen and stored in liquid nitrogen or 
processed immediately. The cords were first homogenised in a 0.85 M sucrose 
with 10 mM HEPES using a polytron homogeniser at full speed for 12 strokes. 
Seven and a half ml of the homogenised tissue was transferred to Beckman SW41 
rotor. Three ml of a 0.25 M sucrose solution in 10 mM HEPES was slowly added on 
top until two obvious phases could be seen. The samples were then spun at 70 
000 x g for 90 minutes at 4˚C. Subsequently, the upper sucrose phase was 
removed and the interface containing the membrane fraction was gently 
aspirated off and transferred to a fresh Beckman tube. This membrane fraction 
was subjected to osmotic shock using 6ml of chilled MilliQ water. The 
myelin/water mix was vortexed then spun at 23 000 x g for 30 minutes in a J21 
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rotor. This step was repeated three times removing all water in-between. The 
final spin was done at 17 000 x g. The myelin pellet that was left was 
resuspended again in 0.85M sucrose and the entire process repeated, but with 
only one osmotic shock treatment at the end. The myelin pellet was then 
resuspended in sterile phosphate buffered saline (PBS see Appendix 7.1.2). 
Protein and phosphatase inhibitors were not used during the myelin preparation. 
 
 
2.4.1 Protein assay 
The protein assay was performed using Peirce protein assay system (Perbio,  
Northumberland) based on the Lowry Method using bicinchoninic acid (BCA) as a 
reagent. Two mg/ml bovine serum albumin (BSA) (Perbio, Northumberland) was 
diluted to 0.05, 0.1, 0.2, 0.4 and 0.6mg/ml with MilliQ water. One ml of BCA 
reagent was added to each of the five standards and to water (all 50 µl volumes) 
and to 5 µl of the myelin samples, which were each assayed in triplicate. The 
samples were then incubated at 37 °C for 30 minutes. Measurement of the 
absorbance of 562 nm wavelength light was then performed using a 
spectrophotometer (Cecil 1100). A standard curve was generated from the 
known standards and the sample concentrations were calculated using the 
standard curve. Myelin stock concentrations were prepared to 2 mg/ml for 
subsequent labelling with NHS-rhodamine antibody labelling kit (Pierce, 
Cramlington, Northumberland).  Prior to labelling with the NHS-rhodamine 
antibody, 10 µl of the prepared myelin sample was incubated at 37 °C for 1 
week in DMEM (Gibco, Invitrogen, Paisley) to check for sterility. 
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2.4.2 SDS PAGE (sodium dodecyl(lauryl)sulphate polyacrylamide 
gel electrophoresis) and western blotting 
 
2.4.2.1 Sample preparation 
To check that the myelin emulsion generated from the isolated Plp1-transgenic 
or wild type spinal cord was enriched for myelin proteins, western blots were 
carried out on selected preparations using antibodies against various myelin 
proteins. Twenty µl of the myelin tissue fraction emulsion was prepared to 1 
mg/ml in PBS including 4 µl of 5 x loading buffer (Sodium dodecyl 
sulfate/Dithiothreitol denaturing buffer (SDS/DTT, see Appendix 7.1.6) and 
heated to 65 ºC for ten minutes to linearise the proteins by denaturing secondary 
and non-disulfide-linked tertiary structures and apply a uniform negative charge 
each protein, prior to running on an acrylamide gel. 
Ten µg of myelin emulsion obtained from the wild type or Plp1- transgenic mice 
was run on a 4-12 % gradient NuPAGE bis-tris acrylamide gel (Invitrogen, Paisley, 
UK) at 200 Volts for between 40 and 50 minutes.  Following a brief wash in 
cathode buffer (see Appendix 7.1.3) the proteins in the gel were then 
transferred using a semi-dry blotting system to a PVDF membrane (Millipore; 
Watford, UK). The gel was placed on top of 1 sheet of blotting paper soaked in 
anode 1 (Appendix 7.1.3.1) buffer, followed by 2 sheets soaked in anode 2 buffer 
(Appendix 7.1.3.2) and a single PVDF membrane. The PVDF membrane had been 
‘wet’ in methanol for 10 seconds, then washed in MilliQ water and finally in 
anode 2 buffer for 5 minutes prior to use. A further 3 sheets of blotting paper 
soaked in cathode buffer (Appendix 7.1.3.3) were placed on top of the gel. Each 
layer was gently pressed using a small roller before the next was applied to 
remove any air bubbles. 
The transfer was carried out at a constant current of 225mA for one hour for two 
gels. To check that the transfer was successful, the blots were briefly stained 
with Ponceau S (see Appendix 7.1.4). PVDF membranes were then washed in tris 
buffered saline (TBS) tween, blocked in 5% milk in 1 X TBS/tween (pH 7.4), 
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incubated overnight with primary antibody in blocking solution at 4°C, with 
gentle agitation, washed and incubated in HRP-conjugated goat anti-mouse or 
goat anti-rabbit secondary antibodies (New England Biolabs; Dundee) in blocking 
solution for 1 hour at room temperature. The secondary antibody was detected 
using enhanced chemiluminescence (ECL) (SuperSignal West Pico, Pierce 
Biotechnology Inc. Perbio Science UK Ltd.) The PVDF membrane was wrapped in 
saranwrap and exposed to x-ray film (AGFA) over a range of exposures from 30 
seconds to 20 minutes to obtain an optimal exposure.  
The primary antibodies used for the western blots were either gifted or 
commercially available and their source and dilutions are illustrated in Table 3. 
Secondary antibodies (either anti-mouse or anti-rabbit, also shown in Table 3.), 
all raised in goat, were conjugated with horse radish peroxidise (New England 
Biolabs; Hertfordshire, UK) and diluted 1:10 000. 
  
Table 3. Western blot antibodies  
 
Primary antibody Dilution Source Secondary 
antibody 
Neurofilament 
light chain (NFL-
68) 
1:10 000 Affiniti Research 
Products Ltd., 
Derbyshire 
Anti-mouse HRP 
Glial fibrillary 
acidic protein 
(GFAP) 
1:200 000 Sigma-Aldrich, 
Dorset 
Anti-rabbit HRP 
CNP  1:5000 Cambridge 
Bioscience, 
Cambridge 
Anti-mouse HRP 
PLP/DM20 (226) 1:50 000 gift from M.P 
Groome 
Anti-rabbit HRP 
 
 
 
 
 
2.4.3 Rhodamine labelling of the isolated myelin 
In order to visualise the phagocytosed myelin, purified myelin was labelled with 
NHS-Rhodamine fluorescent tag using a Rhodamine antibody labelling kit 
following manufacturer’s protocol (Pierce, Cramlington, Northumberland). Forty 
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µl of Borate Buffer (0.67M) was added to 0.5ml of myelin at a concentration of 
2mg/ml protein. 0.5ml of the protein/Borate Buffer mixture was then added 
directly to a vial of NHS-Rhodamine reagent and gently mixed by pipetting up 
and down several times until all the dye was dissolved. The sample was then 
briefly centrifuged (1000 x g for 30-45 seconds) and incubated at room 
temperature for 1 hour, protected from light. While the myelin was incubating 
the purification resin was prepared. Four hundred µl of reuspended purification 
resin was added to two separate spin columns in separate microcentrifugation 
collection tubes. The columns were then centrifuged for 30-45 seconds at 1000 x 
g to remove the storage solution from the resin. The spin columns that contained 
the resin were then transferred to fresh microcentrifugation tubes. After 
incubation, 250µl of the labelled myelin was added to each column and then the 
columns were centrifuged again at 1000 x g for a further 30-45 seconds. The 
samples, containing the fluorescently labelled myelin from both 
microcentrifugation tubes were then combined and the spin columns were 
discarded. The labelled myelin was then stored at -80ºC until required. 
 
2.4.4 Myelin addition to cell culture 
Myelinating cultures were established for 20, 24 or 27 (all ±1 day) days in vitro 
(DIV). Before the myelin was added, the entire medium was removed from each 
well and replaced with fresh differentiation medium minus insulin. Sterile 
(rhodamine-labelled) myelin in PBS, extracted from either wild type or Plp1-tg 
mouse spinal cord was then added directly to the cell culture wells at different 
concentrations and for different durations. From previous studies in which 
myelin was added to cell culture systems, a starting concentration was 
determined. Previous studies used 0.05 mg/ml of myelin (Boven et al., 2006), 
therefore concentrations above and below this were tested. The concentrations 
of myelin tested were 0.025 mg/ml, 0.05 mg/ml, 0.075 mg/ml and 0.1 mg/ml 
for either 7, 3 or 1 days in vitro. To ensure that the myelin was present at 
saturating amounts for all time tested, the final concentrations myelin tested in 
subsequent experiments were 0.075 mg/ml and 0.1 mg/ml.  
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To allow for a uniform solution and facilitate an even distribution, the myelin 
was vortexed thoroughly immediately before adding to the culture medium. An 
equivalent volume of PBS was applied to separate cultures as a control for the 
myelin delivery medium. Three x 106 one µm diameter Flurobite fluorescently 
labelled latex beads (Polyscience, Park scientific, Northampton, UK) were also 
used as a control for phagosytosis per se. At the end of the selected time points 
culture medium was removed from the wells and stored for cytokine analysis.  
The cells were fixed and analysed using immunocytochemistry (see section 2.5 
below)  
 
 
2.4.5 Lipopolysaccharide stimulation of microglia/macrophages 
in vitro 
Lipopolysaccharide (LPS), E-coli mutant O111:B4 (VWR) was added directly to 
the myelinating cultures (100 ng/ml) for 48 hours (Domercq et al., 2007). To 
determine if the known pro-inflammatory effects of LPS were enhanced or 
ameliorated in the presence of myelin-laden microglia/macrophages, Plp1 
transgenic myelin (0.1 mg/ml) was added to the cultures (as described 
previously) 3 days prior to the treatment with LPS. All medium was removed 
then LPS was added for 48 hours. Equivalent volumes of PBS were added to 
separate coverslips as a control. After the entire 5 days incubation, all medium 
was removed for cytokine analysis and the cells fixed and analysed using 
immunocytochemistry.   
 
2.5 Immunocytochemistry 
Medium was aspirated from myelinating cultures and the cells were then 
immediately washed twice in PBS (37oC) to remove any media , then fixed using 
4% paraformaldehyde (37 °C) for 10 minutes. The cells were then permeabilised 
using methanol, at -20 °C for 5 minutes. Non-specific binding sites were blocked 
using 10 % normal goat serum (Sigma-Aldrich, Dorset) in PBS and then the 
cultures were incubated at 4°C overnight in primary antibody in blocking 
solution. The next day, the coverslips were washed 3 times in PBS and the 
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secondary antibody, diluted in blocking solution, was applied for one hour at 
room temperature. After incubation with the secondary antibody, the cells were 
washed again in PBS as before and 0.83 µg/ml -1 4,6-diamidino-2-phenylindole 
(DAPI), a nuclear marker, was applied for 60 seconds. This was followed by 
another brief wash in PBS prior to mounting in antifade mounting medium 
(Citifluor, London).  
The primary antibodies used for immunocytochemistry were commercially 
available and their source and dilutions are illustrated in Table 4. Secondary 
antibodies used were all raised in goat and their source and dilutions are 
illustrated in Table 5. 
  
Table 4. Immunocytochemistry primary antibodies 
 
Primary antibody Isotype Dilution Source 
CD45 Rat IgG1 1:600 AbD Serotec, 
Kidlington 
MBP Rat IgG 1:500 AbD Serotec, 
Kidlington 
GFP Rabbit IgG 1:1000 Abcam, 
Cambridge 
CD68 Rat IgG2a 1:200 AbD Serotec, 
Kidlington 
CD11B 
conjugated FITC 
Rat IgG2b 1:20 BioLegend UK 
Ltd., Cambridge 
SMI31 Mouse IgG1 1:1500 Affiniti Research 
Products Ltd., 
Derbyshire 
ID4B Rat IgG 1:2 Gifted from 
Developmental 
Studies 
Hybridoma Bank, 
University of 
Iowa 
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Table 5. Immunocytochemistry secondary antibodies 
 
Secondary antibody Dilution Source 
Anti-Rabbit Alexa Fluor 
488 
1:1000 Invitrogen 
Anti-Rat Alexa Fluor 488 1:1000 Invitrogen 
Anti-Rat Alexa Fluor 594 1:1000 Invitrogen 
 
 
 
 
2.6 Quantification and statistical analysis 
Quantification of rhodamine-labelled myelin treated cultures was carried out, 
blinded, on 10 randomly selected images of the green (CD45), red (rhodamine) 
and DAPI channels. Images were captured using a x20 objective over two 13 mm 
coverslips per experiment using a CCD camera system (Photonic Science Colour 
Coolview) and  ImagePro 6.0 software (Media Cybernatics, Wokingham, 
Berkshire). Images were selected on the DAPI channel to avoid bias and captured 
from the middle and 4 corners of each coverslip.  
 
 
2.6.1 Quantification of CD45 positive cell density and percentage 
of rhodamine-positive cells in myelin-treated cell cultures 
To calculate CD45 positive cell density, manual counts of CD45 positive cells that 
contained a DAPI-labelled nucleus, within an area of interest (AOI, 124384 sq 
microns), were performed on digital images using ImagePro 6.0 software (Media 
Cybernatics, Wokingham, Berkshire), All cell within the AOI and those touching 
or crossing the north and west borders were counted. Those cells that touched 
or crossed the south and east borders of the AOI were excluded. Densitites were 
presented as cells/mm2. Manual counts were also made of the number of CD45 
positive cells that contained rhodamine-labelled myelin debris. The number of 
CD45 positive cells containing rhodamine was expressed as a percentage of all 
CD45 positive cells. 
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2.6.2 Quantification of the mean area per CD45 positive cell  and 
the mean area occupied by rhodamine-labelled myelin per 
CD45 positive cell 
 
To calculate the mean area per CD45 positive cell, automatic segmentation was 
carried out on digital images of the total CD45 positive staining within a known 
AOI (124384 sq microns) using ImagePro 6.0 software Media Cybernatics, 
Wokingham, Berkshire). The segmented image was then compared to the original 
image and then (if required) adjusted to provide the best representation of the 
original image. The system then automatically quantified the area occupied 
(using a count/size application) by all bright objects within the AOI to give the 
total area occupied by the staining. Prior to application the count/size limits 
were set (calculate area, no borders, holes not filled) and the system calibration 
set to x 20 magnification. The total area was then given in square microns and 
divided by the CD45 cell density to generate an average area per CD45 positive 
cell. The same process was carried out on the red channel (rhodamine) to 
quantify area occupied by myelin. The area given from the automatic count was 
then divided by the density of CD45 positive cells that contained the rhodamine-
labelled myelin to generate the average area of rhodamine-labelled myelin per 
CD45 positive cell. 
 
2.6.3 Quantification of neuritic changes 
Coverslips from each experimental paradigm were assigned a numerical identity 
for the purposes of blinding the assessor. For each independent experiment, five 
images were taken, at random on both the red (MBP) and green (GFP) channels, 
of each of two coverslips per treatment. An AOI of 124384 mm2 was placed on 
each digital image. Manual counts of all CFP positive neurites that crossed a 
horizontal line through the centre of the AOI were performed and the total 
number of neurites recorded. Neurites were then grouped as myelinated or non-
myelinated and categorised by signs of neuritic changes. Neurites were 
examined and characterised as either (i) normal, (ii) beaded (small focal 
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swellings <20 µm2 along otherwise intact neurites), (iii) degenerate/transected 
(fragmented or severed) or (iv) focally swollen but intact (swellings greater than 
20 µm2). 
 
2.7 Time lapse imaging 
 
To observe myelin uptake and degradation, time lapse imaging was carried out 
on myelinating cultures (see 2.2.2) plated on 35 mm glass bottom Petri dishes 
(MatTek corporation, Ashland, USA) and cultured for 20-22 days in vitro (DIV). 
Immediately prior to imaging, 0.05 mg/ml of rhodamine-labelled myelin tissue 
fraction was vortexed and added directly to the culture Petri dish. The culture 
was then set in a Nikon TE 2000 time lapse microscope inside a 
temperature/CO2 controlled chamber. Using Metamorph 7.5.2 imaging software 
set for multi-stage positions and multiple wavelengths, positions of interest were 
then selected on the bright field (phase) Cherry (rhodamine) and CFP channels 
and the co-ordinates recorded. Focus for each position was then set using a PSF 
perfect focus control. Images were taken of each position on each channel every 
five minutes over a 15 hour period. AVI videos of the stills collected were then 
generated using ImageJ software.      
 
 
2.8 Proteome array analysis of culture medium 
2.8.1 Sample preparation and application 
Medium collected from myelinating cells cultures, which had been incubated in 
the presence of either wild type or Plp1-tg myelin (0.1 mg/ml), 3 x106 Flurobite 
latex beads or PBS, for either 1, 3 or 7 days, was tested for 40 different 
cytokines/chemokines (see Appendix 2) using a mouse cytokine array panel A kit 
(R&D systems, Abingdon). Sample preparation and procedure were carried out 
according to manufacturers’ protocol. All kit solutions were brought to room 
temperature prior to use and culture medium samples were thawed and kept on 
ice. The cell culture medium was first centrifuged using a Sigma desktop 
centrifuge at 12470 x g for 1 minute to remove any cellular or myelin debris. 
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Next, four cytokine nitrocellulose membrane panels were placed in a 4-well 
Multi-dish in 2 ml of blocking buffer (Array Buffer 6 supplied in kit) and placed 
on a rocking platform to incubate for one hour at room temperature. Whilst the 
membranes were blocking, up to 1 ml of each of the samples was added to 0.5 
ml of Array Buffer 4 (supplied in kit). If the volume of sample was less than 1 ml, 
the final volume of the mix was adjusted to 1.5 ml using Array Buffer 5 (supplied 
in kit). Fifteen µl of a reconstituted (in 100 µl of deionised water) Cytokine Array 
Panel A Detection Antibody cocktail (supplied in kit) was then added to each 
sample and then incubated at room temperature for one hour. After incubation, 
the Array Buffer 6 was aspirated from the 4-well Multi-dish and the 
sample/antibody mixture was then added to each of the four membranes and 
incubated at 4 ºC  over night on a rocking platform. The next day, the 
membranes were carefully removed from the 4-well Multi-dish and placed into 
individual containers containing 20 ml of 1 x Wash Buffer (25 x Wash Buffer 
supplied in kit diluted in deionised water) for 3 x 10 minutes. After being washed 
to remove excess sample/antibody mix, the membranes were carefully 
transferred back into the 4-well Multi-dish containing 1.5 ml of Streptavidin-HRP 
(supplied in kit) diluted in Array Buffer 5 (1:2000) in each well. The membranes 
were then incubated at room temperature for 30 minutes and then washed as 
before 3 x 10 minutes in 20 ml 1 x Wash buffer. Membranes were exposed to 
chemiluminescent detection reagents ECL (Super signal West Pico 
chemiluminescent substrate, Pierce) and wrapped in Saranwrap and exposed to 
x-ray film (AGFA) for various exposure times between 30 seconds to 10 minutes.   
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3 Characterisation of myelin-laden 
microglia/macrophages in vitro 
3.1 Introduction 
Microglia, which are derived from primitive myeloid progenitors (Ginhoux et al., 
2010), are the resident macrophages of the CNS. They enter the CNS from the 
periphery during embryogenesis, and in the mouse, can be observed in the spinal 
cord as early as embryonic day 11.5 (E11.5) (Rigato et al., 2011).  Microglia 
continuously survey the CNS environment (Nimmerjahn et al., 2005;Wake et al., 
2009) and help maintain homeostasis (Aloisi, 2001;Neumann et al., 2009).  Their 
phagocytic activity represents one of the first mechanisms of defence against 
invading microorganisms and is also important in the removal of damaged tissue, 
for example, during demyelination (Neumann et al., 2009;Walter and Neumann, 
2009) and in response to apoptosis (Peri and Nusslein-Volhard, 2008;Nakamura et 
al., 1999).  
Microglia are exceptionally sensitive to the micro-environment in which they 
reside, and respond to tissue injury by altering their phenotype from an 
‘inactive’ (though motile) down regulated one to an ‘activated’ one (Perry et 
al., 2010).   ‘Activation’ of microglia/macrophages in vivo is associated with 
increased proliferation (Ip et al., 2008), production of inflammatory cytokines 
and chemokines (Palin et al., 2008;Zhang et al., 2001) and morphological 
changes (Walter and Neumann, 2009). Changes in morphology and in 
cytokine/chemokine profiles also occur in response to activating stimuli in vitro 
(Beyer et al., 2000).  
In the optic nerve of the Plp1 overexpressing mouse, sites of acute axonal 
transport impairment correlate with active demyelination and elevated densities 
of CD45 positive microglia/macrophages (Edgar et al., 2010); many of which 
contain myelin debris. These observations led to the suggestion that the 
phagocytosis of large amounts of myelin debris may drive 
microglia/macrophages towards an ‘activated’ axono-toxic phenotype.  This, in 
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line with in vitro studies that show that the phagocytosis of a myelin-enriched 
tissue fraction (mimicking myelin debris) by isolated microglia or macrophages in 
vitro triggers the production of pro-inflammatory cytokines and nitric oxide 
(Williams et al., 1994;Mosley and Cuzner, 1996), both of which have been shown 
to impair axonal transport in vitro (Stagi et al., 2006;Stagi et al., 2005).  
However, the effects of the phagocytosis of myelin on the status of 
microglia/macrophage are controversial and more recent studies suggest that 
ingestion of myelin by this population, triggers an anti-inflammatory response 
(Boven et al., 2006;Liu et al., 2006). 
In this thesis, an in vitro model of myelination (Thomson et al., 2008) was used 
to test the hypothesis that myelin-laden microglia are axono-toxic.  Myelin-laden 
microglia/macrophages were generated through the addition of an exogenous, 
myelin-enriched tissue fraction to the cultures. Before beginning these 
experiments, it was important to determine optimal conditions for generating 
myelin-laden microglia/macrophages and to characterise the microglial 
population in the myelinating culture system.  
The aims of this chapter were to: 
1. Confirm that microglia are present in the E13 mouse spinal cord from 
which the myelinating cultures are generated. 
2. Confirm that the intrinsic microglial/macrophage population in the 
myelinating culture system is capable of phagocytosing exogenous myelin 
debris 
3. Determine the optimal parameters for generating myelin-laden 
microglia/macrophages 
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4. Assess putative phenotypic changes in myelin-laden 
microglia/macrophages. 
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3.2 Materials and methods 
3.2.1 Myelinating cultures 
Myelinating cultures were established from spinal cords of E13 Thy1-CFP mouse 
embryos, as described in Chapter 2.2. 
3.2.2 Immunohistochemistry of E13 spinal cord  
Embryonic mouse spinal cords, prepared as for the myelinating cultures (i.e. 
having been stripped of their meninges) were immersion fixed, frozen and 
sectioned on a cryostat (Chapter 2.3).  Sections were immunostained with 
antibodies against CD45 (a pan-leukocyte marker) or CD68 (a macrophage-
specific marker). Tissue sections from the spleen of a P90 Plp1-transgenic mouse 
were used as positive controls for immunohistochemistry (Chapter 2.3.4). 
3.2.3 Preparation of a myelin-enriched tissue fraction 
A myelin enriched tissue fraction from adult wild type or Plp1-transgenic mice 
was prepared according to the protocol of (Norton and Poduslo, 1973) with 
minor modifications (See Chapter 2.4). 
3.2.4 SDS PAGE and western blot of myelin-enriched tissue 
fraction 
To confirm myelin enrichment, the myelin fraction was analysed by western blot 
(Chapter 2.4.2).  Equal amounts of a myelin-enriched tissue fraction and a total 
spinal cord homogenate were subjected to SDS-PAGE then transferred to a PVDF 
membrane (Chapter 2.4.2).  Membranes were probed with antibodies against the 
myelin proteins CNP and PLP/DM20, and against astroglial and neuronal proteins, 
GFAP and NF68, respectively (Chapter 2.4.2, Table 3). The remaining myelin 
fraction was diluted to 2 mg of protein ml-1 and tested for sterility (Chapter 
2.4.1), then labelled with an NHS-rhodamine antibody labelling kit (Chapter 
2.4.3). 
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3.2.5 Quantification of myelin up-take by microglia/macrophages 
and analysis of ‘activation’ parameters 
Cultures were treated with various concentrations (0.025 – 0.1 mg protein ml-1) 
of rhodamine-labelled myelin-enriched tissue fraction in PBS, with 3 x 106 
Flurobrite fluorescently labelled latex beads in PBS, or with PBS alone, at DIV 21 
(± 1 day), 25  (± 1 day) or 27  (± 1 day), then fixed on day 28 (± 1 day).  Cultures 
were immunostained with an antibody to CD45 and labelled with DAPI (Chapter 
2.5).  Myelin up-take, CD45 positive cell size and density were quantified from 
minimum of three independent experiments (Chapter 2.6).  
3.2.6 Time lapse imaging of rhodamine-labelled myelin treated 
cultures 
A rhodamine-labelled myelin-enriched tissue fraction (0.05 mg of protein ml-1) 
was added to 20 DIV cultures. Time-lapse imaging was carried out immediately 
afterwards, over a 15 hour period. Images were taken on bright field (phase 
contrast), ‘cherry’ (rhodamine) and CFP/YFP (neurites) channels with 5 minute 
intervals between frames (Chapter 2.7).  For each area imaged, a composite 
movie was generated from the bright field and cherry channels.  
3.2.7 Lipopolysaccharide treatment of myelinating cultures 
LPS was added to the myelinating cultures at 23 DIV, for 48 hours, following 
incubation of the cultures with myelin (0.1 mg protein ml-1) or PBS on DIV 20 
(Chapter 2.4.4).  Culture medium was collected and stored at -80oC (see 
Chapter 5.2.2) and cells were immunostained with an antibody against CD45 
(Chapter 2.5).  Images of microglia/macrophages were captured using both 
phase-contrast and fluorescence microscopy.   
3.2.8 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 5 software. The 
percentage of CD45 positive cells taking up myelin over 3 time points was 
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analysed using one way ANOVA.  Comparisons between wild type and Plp1-
transgenic myelin treated cultures at specific time points and specific 
concentrations of myelin were made using an unpaired Student’s t-test. 
Changes in CD45 positive cell density and cell size after 7 days incubation with 
the myelin-enriched tissue fraction was also analysed using one way ANOVA.  
Comparisons between the myelin- or bead-treated cultures and the PBS treated 
controls were made using one-way ANOVA followed by Dunnett’s multiple 
comparison test.  Significance was set at p < 0.05. 
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3.3 Results 
3.3.1 CD45 positive cells in the E13 mouse spinal cord 
parenchyma  
To determine the origin of the CD45 positive cells in the myelinating cultures, a 
section of embryonic day 13 spinal cord was immunostained with antibodies 
against CD45 and CD68.  Both CD45 (Figure 1A) and CD68 (Figure 1B) positive 
cells, with the morphology of microglia, were observed in the parenchyma of the 
E13 spinal cord. Therefore it was concluded that at least some of the CD45 
(Figure 2A), CD11B (Figure 2B) or CD68 (Figure 2C), positive cells in the cultures 
(see later) were resident microglia.  However, CD45 and CD68 positive cells were 
also evident in blood vessels and around the outer surface of the cord and are 
probably monocytes.  
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Figure 1: Microglia/macrophages in the parenchyma of E13 mouse spinal cord. 
Micrographs of mouse spinal cord stained with (A) DAPI (left) and antibody to CD45 
(right), a pan leukocyte marker, indicating CD45 positive cells within the parenchyma 
(arrows).  Insert: high magnification image of a CD45 positive cell with a DAPI stained 
nucleus.  (B) Same spinal cord stained with DAPI (left) and with an antibody to CD68 
(right), a phagocyte specific marker, indicating the presence of CD68 positive cells 
within the cord parenchyma (arrows).  Insert: high magnification image of a CD68 
positive cell with a DAPI stained nucleus.  Scale bar 50 µm   
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Figure 2: Microglia/macrophage are present in the myelinating cultures at 20 
DIV.  Micrographs of myelinating cultures stained with (A) CD45, (B) CD11b and (C) 
CD68 showing the presence of microglia/macrophages within the myelinating 
cultures.  Scale bar 50 µm 
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3.3.2 Western blot analysis confirms that a myelin-enriched 
tissue fraction was obtained 
To confirm that the tissue fraction obtained from adult mouse spinal cord was 
enriched for myelin, a sample of wild type ‘myelin’ emulsion was run alongside a 
wild type spinal cord total homogenate and analysed using western blot with 
antibodies against CNP, PLP/DM20, GFAP and NFL-68.  Western blots 
demonstrated higher steady state levels of CNP and PLP/DM20 in the myelin 
fraction compared to the total spinal cord homogenate (Figure 3, lower two 
blots).  In contrast, GFAP and NFL-68 were enriched in the total spinal cord 
homogenate (Figure 3, upper two blots), as indicted by the absence of a signal in 
the myelin containing lane. Therefore, it was concluded that the fraction 
obtained following the myelin enrichment protocol described in Chapter 2 
(subsequently referred to as myelin) was enriched in myelin-specific proteins.  
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Figure 3:  Western blotting of a total and a myelin-enriched tissue fraction.  
Western blots of 5µg of wild type total spinal cord homogenate and a myelin-
enriched tissue fraction generated from adult (P60) wild type spinal cord, showing 
enrichment of myelin specific proteins in the myelin-enriched tissue fraction.  Blots 
were probed with mouse anti-NFL-68 (68 kDa), rabbit anti-GFAP (55 kDa), mouse 
anti-CNP (48 kDa) and rabbit 226 antibody (which recognises PLP and DM20, 25 kDa 
and 20 kDa respectively).  Specific myelin proteins were present in both the spinal 
cord total homogenate and the isolated myelin tissue fraction. However astroglial 
and neuronal proteins were only detected in the total spinal cord homogenate.   
Images obtained from exposures of X-ray film for between 1 and 5 minutes. 
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3.3.3 Myelin is phagocytosed by microglia/macrophages in vitro 
To determine if the intrinsic microglial population in the myelinating cultures is 
capable of phagocytosing myelin debris, cultures were treated with various 
concentrations of rhodamine-labelled myelin for increasing incubation times.  
Rhodamine-labelled myelin was visible within CD45 positive cells within 24 hours 
of treating the cultures, demonstrating that microglia/macrophages phagocytose 
myelin debris in vitro (Figure 4).  The rhodamine staining was never observed in 
the cell nucleus and the pattern appeared punctuate, suggesting that the 
labelled myelin was contained within endosomes/lysosomes. This was confirmed 
by co-labelling with an antibody, ID4B, against a lysosomal membrane protein, 
lysosomal associated membrane protein 1 (LAMP1) (Figure 5).   
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Figure 4:  CD45 positive cells phagocytose Rhodamine-labelled myelin in vitro. 
CD45 staining of myelin treated cultures at 27 DIV.   (A) FITC labelled CD45 positive 
cells after incubation with myelin for 7 days.  (B) Rhodamine labelled wild type 
myelin in the same culture.  (C) Merge of images (A) and (B) shows co-localisation of 
the CD45 positive staining and the rhodamine labelled myelin.  Scale bar: 50 µm. 
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Figure 5: Rhodamine-labelled myelin debris is observed in lysosomes within 
microglia/macrophages in vitro. ID4B staining of cultures treated with rhodamine-
labelled myelin at 27 DIV. (A)  FITC labelled ID4B positive late endosomes/lysosomes 
within microglia/macrophages 7 days after treatment with rhodamine-labelled myelin 
(B).  Merge of images (A), (B) and DAPI (C) shows rhodamine-labelled myelin debris 
within ID4B positive lysosomes (arrows).  Scale bar 10 µm   
 
 
 
Figure 5: Rhodamine-labelled myelin debris is observed in lysosomes within 
microglia/macrophages in vitro. ID4B staining of cultures treated with rhodamine-
labelled myelin at 27 DIV. (A)  FITC labelled ID4B positive late endosomes/lysosomes 
within microglia/macrophages 7 days after treatment with rhodamine-labelled 
myelin (B).  Merge of images (A), (B) and DAPI (C) shows rhodamine-labelled myelin 
debris within ID4B positive lysosomes (arrows).  Scale bar 10 µm   
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3.3.4 Motile microglia/macrophages take-up myelin in vitro, but 
do not rapidly degrade it 
To visualise myelin uptake and breakdown by the microglia/macrophages in 
vitro, cultures were imaged using time-lapse microscopy in the presence of a 
low concentration of rhodamine-labelled myelin (see attached CD for video). 
Time-lapse imaging demonstrated that this cell population was highly motile in 
vitro as illustrated by following a single cell over time (Figure 6 B-G). Within 35 
minutes of the addition of myelin to the culture, cells could be observed taking 
it up. Over the 15 hour imaging period, these cells progressively internalised the 
myelin debris (Figure 6 B-H). As microglia/macrophages surveyed their 
environment, they sent out cell processes, apparently to ‘pick up’ the myelin 
debris (Figure 6 A). The cell processes then retracted and appeared to pull the 
debris towards the cell body (Figure 6 B).  While the uptake and internalisation 
of the myelin debris could be observed during the 15 hour imaging period, 
myelin degradation was not evident.   
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Figure 6:  Time lapse imaging of rhodamine-labelled myelin debris treated culture 
showing myelin uptake and microglia/macrophage motility. Time lapse image stills 
taken over 1095 minutes showing phagocytosis of labelled myelin fraction (red).  
Rhodamine-labelled myelin debris (0.05 mg/ml) was added to myelinating cultures at 
20 DIV.   Images show that some labelled myelin debris is still present at 240 minutes 
after its addition at time 0 (A-D)(circled). Myelin-containing cells can be observed 
within 35 minutes of the addition of myelin to the cultures (*) and appear to have 
completely cleared the myelin debris by 1095 minutes (B-H).  The 
microglia/macrophages are highly motile as they clear up the myelin debris. Using 
time-lapse, the path of a single cell can be mapped over time (B-G, arrows).  
Microglia/macrophages can be seen sending out cellular processes as they take up 
myelin debris (A, arrow heads) and then retract these processes as they pull the 
myelin debris towards the cell body (B). Scale bar 50 µm. 
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3.3.5 Quantification of myelin uptake  
In order to assess how the phagocytosis of myelin by microglia/macrophages 
influences their phenotype, the concentration of myelin that represented 
saturating levels, was first determined. The proportion of CD45 positive cells 
containing exogenous myelin in cultures treated with increasing amounts of 
myelin for 24 hours was 25.29  ± 2.14%, 43.95  ± 8.24%, 66.66  ± 10.51% and 
65.62  ± 13.22% (mean ± s.e.m; n =2 or 3 per myelin concentration) at 0.025, 
0.05, 0.075 and 0.1 mg protein ml-1, respectively. These data suggest that at 
0.075 and 0.1 mg protein ml-1, myelin is present at saturating amounts and 
subsequent studies were undertaken using these concentrations. 
The proportion of CD45 positive cells that phagocytosed wild type or Plp1-
transgenic myelin did not change significantly (p > 0.05) with increasing 
incubation times (Figure 7 A).  This, despite the fact that even after incubation 
for 7 days, myelin debris, which was visible under phase contrast, was still 
available for phagocytosis.    
To determine if myelin debris accumulated or was degraded with increasing 
incubation times, saturating concentrations of myelin were added to the 
cultures for 1, 3 or 7 days. The mean area of rhodamine-labelled myelin per 
CD45 positive cell was calculated, as an approximate measure of steady state 
levels.  The results showed that there was no significant difference (p > 0,05) in 
the mean area of myelin per CD45 positive cell, with increasing myelin 
concentration or incubation time, in cultures treated with either wild type of 
Plp1-transgenic myelin (Figure 7 B).   
Although there were slight differences in the average percentage of CD45 that 
had incorporated myelin and in the mean area of myelin per CD45 positive cell, 
between the wild type and the Plp1-transgenic myelin treated cultures, this was 
caused by a low number of CD45/rhodamine positive cells in one of the Plp1-
transgenic myelin-treated cultures. 
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Graph 7:  In the presence of saturating amounts of myelin debris the percentage 
of CD45 positive cells and mean area of myelin per CD45 positive cell in myelin 
treated cultures is unaltered.  (A) After incubation with saturating amounts of 
myelin debris over three different time points, the percentage of cells that had 
phagocytosed myelin was calculated.  There was no significant change in the 
percentage of CD45 positive cells that contained phagocytosed myelin with 
increasing myelin concentration or with increasing time.  (B) The mean area of 
myelin per CD45 positive cell did not change with increasing incubation times, for 
myelin of either genotype. However, the results only represent the steady state 
levels of the myelin and do not take account for myelin incorporation or 
degradation. Bars represent means +s.e.m.. (n = 3 independent experiments per 
condition).   
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3.3.6 The phagocytosis of myelin debris does not alter CD45 
positive cell morphology or density in vitro 
To determine if the phagocytosis of myelin debris led to morphological changes 
in microglia/macrophages, cultures incubated with saturating concentrations of 
either wild type or Plp1-transgenic myelin on DIV 21 (± 1 day), 25 (± 1 day) or 27 
(± 1 day), were assessed on day 28 (± 1 day).  Qualitatively, there was no 
obvious change in CD45 positive cell morphology or density in the myelin or 
latex–bead treated cultures compared to PBS-treated controls, even after 
incubation with myelin for 7 days (Figure 8 A-D).   
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Figure 8:  Microglial morphology appears similar in myelin or latex bead-treated 
cultures compared to PBS-treated control cultures.  CD45 staining of cultures 
treated with PBS, latex beads or  rhodamine-labelled wild type or Plp1-transgenic 
myelin for  7 days (A-D) CD45 +ve cell morphology and density appears unaltered in 
cultures treated with either wild type (WT) (C) or Plp1-tg (D) derived rhodamine-
labelled myelin debris, compared to latex bead- (B) or PBS- (A) treated controls.  
Arrows indicate intense staining that is due to bleed-through into the green channel 
from the latex beads or the rhodamine-labelled myelin.  Scale bar 20 µm. 
 
Chapter 3  73 
To determine if myelin debris led to proliferation of CD45 positive cells, CD45 
positive cell densities were compared between myelin- and bead-treated 
cultures or between myelin- or bead-treated cultures and PBS-treated controls.  
The density of CD45 positive cells was similar in cultures treated with saturating 
concentrations of myelin or with latex beads, after all incubation times. The 
density of CD45 positive cells in cultures incubated with myelin or latex beads 
for 7 days, was not significantly (p > 0.05) different from that in cultures treated 
only with PBS (Figure 9 A) suggesting that there was no increase in proliferation 
of CD45 positive cells in response to the presence or phagocytosis of myelin 
debris. 
To determine if the phagocytosis of myelin debris resulted in a change in cell 
size, the average area per CD45 positive cell was determined.  The mean area 
per CD45 positive cell was similar in myelin or latex-bead treated cultures after 
all incubation times (Figure 9B).  The mean area per CD45 positive cells in 
cultures incubated with myelin or latex beads for 7 days was not significantly 
different (p > 0.05) from that in cultures treated only with PBS (Figure 9B).  This 
was consistent for cultures treated with either the wild type or Plp1-transgenic 
derived myelin debris.  These results suggested that the phagocytosis of a 
myelin-enriched fragment per se was not sufficient to cause a change in CD45 
positive cell size, an indicator of activation. 
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Figure 9:  The phagocytosis of myelin has no effect on CD45+ve cell density or cell 
size. (A) The density of CD45 +ve cells was similar in cultures incubated with 
rhodamine-labelled myelin or with latex beads, for 1, 3 or 7 days. Statistical analysis 
showed that there was no significant change in the density of CD45 positive cells in 
the myelin or bead-treated cultures compared to the PBS treated controls, 7 days 
after treatment of the cultures.  (B) Mean area per CD45 positive cell was similar in 
myelin and bead treated cultures after all incubation times. There was no significant 
difference in the mean area per cell in cultures treated with myelin or latex beads 
for 7 days, compared to PBS-treated control cultures. Bar represent means +s.e.m.. 
(n = 3 independent experiments per condition). 
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3.3.7 Microglia/macrophages in the myelinating cultures acquire 
an altered morphology after stimulation with endotoxin. 
In light of the observations described above, it was important to determine if 
the microglia/macrophages in the myelinating culture system were already 
maximally activated as a result of the culture process, and therefore insensitive 
to stimulation.  To test this, cultures were treated with LPS.  In contrast to 
cultures treated with myelin debris or with PBS alone (Figure 10 A-B), there was 
an obvious change in the morphology of microglia/macrophages in LPS-treated 
cultures, whether the cells were previously treated with or without myelin 
(Figure 10 C-D).  LPS-stimulated cells adopted a darker and more ‘jagged’ 
appearance compared to non-stimulated PBS-treated controls, when imaged 
under phase-contrast.  Immunostaining with an antibody against CD45 confirmed 
the morphological changes were in the CD45+ve cell population (Figure 11). 
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Figure 10: Lipopolysaccharide (LPS) induces morphological changes in cells 
resembling microglia/macrophages in vitro. Phase images of microglia/macrophages 
in myelinating cultures treated with either (A) PBS, (B) wild type (WT) myelin debris, 
(C) 100 ng/ml LPS or (D) myelin debris followed by 100 ng/ml LPS. There is no 
obvious change in microglia/macrophage morphology in cultures treated with myelin 
debris (B) compared to PBS treated controls (A).  In both conditions the cells have an 
amoeboid appearance. However, after incubating with LPS there is an obvious 
morphological change in the microglia/macrophage from an amoeboid to a more 
‘jagged’ appearance (C). This morphological change was observed in cultures treated 
with LPS in the presence or absence of myelin debris.  Scale bar 50 µm. 
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Figure 11: Lipopolysaccharide (LPS) induces morphological changes in CD45 
positive cells in vitro. Images of CD45 stained cells in myelinating cultures.  Cultures 
were treated with either (A) PBS, (B) WT myelin debris, (C) 100 ng/ml LPS or (D) 
myelin debris followed by 100 ng/ml LPS. There is no obvious change in CD45 positive 
cell morphology in cultures treated with myelin debris (B) compared to PBS treated 
controls (A),. However, after incubation with LPS there is an obvious morphological 
change in the microglia/macrophages (C). This morphological change was observed in 
cultures treated with LPS in the presence or absence of myelin debris.  Scale bar 50 
µm. 
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3.4 Discussion  
The principal aim of this chapter was to optimise conditions for obtaining 
myelin-laden microglia/macrophages in the myelinating culture system.  The 
system was then used to characterise a number of parameters (Perry et al., 
2010;Walter and Neumann, 2009) to determine if the phagocytosis of an 
enriched myelin fraction was sufficient to cause morphological and proliferative 
changes in this population. The data presented in this chapter demonstrated 
that microglia/macrophages efficiently phagocytose exogenous myelin debris.  
However, there was no evidence that this led to changes in morphology or 
proliferation that are generally associated with ‘activation’ of these cells. 
It was confirmed that the spinal cord parenchyma of the E13 mouse embryos 
contained microglia, as shown previously (Rigato et al., 2011). Therefore it can 
be concluded that at least a proportion of the CD45 positive cells in the 
myelinating cultures, were resident microglia.  However, some contamination of 
the cultures by peripheral monocytes, present in blood vessels and in the sub-
arachnoid space was likely.  
Once it was established that the CD45 positive cells were capable of 
phagocytosing myelin debris, the concentration of myelin that represented 
saturating amounts was determined.   As demonstrated previously (Hikawa and 
Takenaka, 1996) phagocytosis occurred in a ‘dose-dependent’ fashion, such that 
increasing myelin concentrations resulted in an increase in the proportion of 
myelin-containing CD45 positive cells.  At concentrations equal to or above 0.075 
mg/ml, the percentage of CD45 positive cells that incorporated myelin debris 
attained maximum levels.  
The data suggest that only a proportion of CD45 positive cells phagocytosed 
myelin debris, even after incubation with saturating amounts of myelin for 7 
DIV.  This probably partly reflects the fact that after fixation and 
permeabilisation, the rhodamine signal faded, making some of the myelin 
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invisible. Indeed, observation of the cultures prior to fixation indicated that 
most cells with the morphology of microglial/macrophages contained at least 
some rhodamine labelled myelin.  Since CD45 is a pan-leukocyte marker, it is 
also possible that the cultures were contaminated by T or B-lymphocytes. 
However, immunostaining with an antibody against CD3, which stains T-cell 
lymphocytes, showed very few (only 2 or 3 cells per 13 mm diameter cover slip) 
T-cells were present. B-lymphocytes were not specifically examined, but in the 
absence of significant numbers of T-lymphocytes, it seems unlikely that B-
lymphocytes contributed. 
In the presence of saturating amount of myelin debris there was no change with 
increasing time, in the area of myelin per CD45 positive cells. This could 
indicate that myelin debris is being taken up and broken down at a similar rate. 
Alternatively, if it is assumed that maximum uptake is attained within 1 DIV, the 
cells could begin to regulate the rate of myelin phagocytosis and degradation 
with simultaneous activation and down-regulation of the microglial/macrophage 
response (Gitik et al., 2011).  (Gitik et al., 2011) and colleagues showed that, 
while activation of phagocytosis occurred following the binding of myelin to 
complement receptor-3 on the microglial cell surface, phagocytosis could also be 
down-regulated by the binding of myelin CD47 epitope to the immune inhibitory 
receptor signal regulatory protein-α (SIRPα), which also resides on the cell 
surface.  Attempts were made to examine the dynamics of myelin uptake and 
degradation using time-lapse imaging. However myelin breakdown was not 
observed during the 15 hour image capture period, therefore it was not possible 
to draw a definitive conclusion. 
To assess the putative effects of phagocytosis of myelin on 
microglia/macrophages population in vitro, cultures were treated with either 
wild type or Plp1-transgenic myelin. This was done to determine if the Plp1-
transgenic myelin, which is biochemically abnormal (Karim et al., 2007) had a 
different effect compared to wild type myelin. In fact, no difference was 
observed in cell size, density or morphology whether the cells were treated with 
myelin of either type compared with PBS alone.   
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To exclude the possibility that the microglia/macrophages within the 
myelinating cultures were insensitive to stimulation, due to being maximally 
‘activated’ as a result of the culture procedure alone, the cultures were treated 
with LPS (Domercq et al., 2007). A previous study, in which isolated neonatal rat 
microglia were treated with a low dose of LPS, showed dramatic changes to 
microglia cell morphology within 3 hours of incubation (Nakamura et al., 1999). 
In that study it was found that peak stimulation with LPS was at 6 hours when 
many cells had changed from an “amoeboid shape to a bipolar rod shape” 
(Nakamura et al., 1999).   Treating the myelinating cultures used in the current 
study with LPS showed similar marked change in cell morphology, suggesting 
that the microglia/macrophages in the culture system remained sensitive to 
‘activating’ stimuli.   
The ‘activation’ of microglia as a result of the phagocytosis of CNS glial 
membranes in vitro is associated with phenotypic changes including increased 
proliferation, increased phagocytic activity and change in morphology (Beyer et 
al., 2000).   In contrast, in the myelinating cultures used in the current study, no 
obvious change in CD45 positive cell morphology and no significant change in 
density or size of the CD45 positive cells, was observed, even after incubation in 
saturating amounts of myelin for up to 7 days. Also, in contrast to earlier 
findings (Beyer et al., 2000), there was no evidence that the phagocytosis of 
latex beads led to a change in the morphology of microglia/macrophages within 
the myelinating culture system.  
The difference between the results obtained in Beyers’ study and in the current 
study may arise for two reasons.  First, (Beyer et al., 2000) treated cultures with 
isolated cellular membranes from either neuronal or glial origin while the 
cultures in the current study were incubated with an isolated enriched myelin 
fraction. Secondly, in contrast to the studies of (Beyer et al., 2000) and others 
(Williams et al., 1994;Boven et al., 2006), in which murine or human derived 
microglia/macrophages were cultured in isolation, the myelinating culture 
system is a mixed cell culture in which microglia/macrophages reside along with 
other neural populations 
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With this in mind, the single cell-type system (Beyer et al., 2000) is less similar 
to the in vivo situation, in which multiple cell types interact, than the system 
used in the current study. It is possible that isolated microglia/macrophages 
respond differently to stimuli compared to microglia in mixed cell culture. 
Certainly, there is cross-talk between cells of the immune system and neural 
cells (Kerschensteiner et al., 2009) that could potentially influence the 
responses of microglia/macrophages.  There is increasing evidence that the dual 
role of the immune system, which can shift from a neurotoxic to a 
neuroprotective phenotype, is a result of overlapping cross-talk from factors 
secreted by both the immune (cytokines/chemokines) and nervous (neurotrophic 
factors) systems, neither of which is exclusive to either system (Kerschensteiner 
et al., 2003).  
Previous studies investigating the effects microglia/macrophage ‘activation’ as a 
result of phagocytosis showed that the phagocytosis of human derived myelin 
could drive microglia/macrophages towards either a pro- (Williams et al., 1994) 
or anti-inflammatory (Boven et al., 2006) response.  In these studies, 
microglia/macrophage ‘activation’ was measured by cytokine/chemokine 
secretion and not by a change in cell density or morphology.  The 
cytokine/chemokine profile of the myelin-laden microglia in the current study 
will be described in Chapter 5.  
From the in vitro characterisation of the CD45 positive microglia/macrophages, 
it can be concluded that the phagocytosis of a myelin-enriched tissue fraction 
does not cause morphological and proliferative changes that are generally 
associated with microglial/macrophage activation. Nonetheless, the process of 
isolating the spinal cord cells and maintaining them under cell culture conditions 
is itself, likely to change the phenotype of the cells and this could potentially 
mask subtle alterations. 
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4 The effects of myelin-laden 
microglia/macrophages on neuritic integrity in 
an in vitro model of myelination 
4.1 Introduction  
Axonal loss is the main determinant of permanent neurological disability in MS 
(Ferguson et al., 1997;Bjartmar et al., 2003;Trapp et al., 1998b) However, there 
remains uncertainty regarding the nature of the cellular factors that elicit 
axonal injury.  In the Plp1-overexpressing mouse, a non-immune mediated model 
of demyelination, sites of acute axonal changes are most prevalent in regions of 
active demyelination where microglia/macrophages are phagocytosing myelin 
debris (Edgar et al., 2010) raising the possibility that myelin-laden 
microglia/macrophages are axono-toxic. However, the literature regarding 
myelin-laden macrophages is contradictory, with both pro-inflammatory 
(potentially axono-toxic) and anti-inflammatory (potentially axono-protective) 
properties having been demonstrated ((van der Laan et al., 1996;Williams et al., 
1994;Boven et al., 2006;Mosley and Cuzner, 1996)).  The results presented in 
Chapter 3 demonstrated that in an in vitro model of myelination, 
microglia/macrophages phagocytose an exogenous myelin-enriched tissue 
fraction.  Here I used this mixed neural cell system to assess if myelin-laden 
microglia/macrophages exert either axono-toxic or axono-protective effects in 
vitro. The aims of this chapter were: 
1. To develop a sensitive method for assessing and quantifying neuritic 
injury in vitro 
2. To determine if myelin-laden microglia/macrophages injure or protect 
adjacent myelinated and non-myelinated CFP expressing neurites in an in 
vitro model of normal or inflamed CNS white matter.  
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4.2 Methods 
4.2.1 Generation of myelinating cultures 
Myelinating cultures were established from spinal cords of E13 Thy1-CFP mouse 
embryos and their wild type littermates, as described in Chapter 2.2. 
4.2.2 Generation of myelin-laden microglia/macrophages 
At 21 (± 1) DIV a sterile myelin-enriched tissue fraction, derived from either wild 
type or Plp1-tg mice (Chapter 2.4), was added directly to culture medium at a 
final concentration of 0.1 mg/ml.  Cultures were incubated with myelin debris 
for 1 or 7 days, to determine if myelin-laden microglia-macrophages were 
detrimental to neighbouring neurites (Chapter 2.4.3), or for 3 days to generate 
myelin-laden ‘foamy’ microglia/macrophages to assess their putative axono-
protective affects in the presence of LPS (Chapter 2.4.4). 
4.2.3 Quantification of neuritic integrity  
Cultures treated with (i) wild type or Plp1-tg myelin debris (Chapter 2.4.3) or (ii) 
myelin debris then LPS (Chapter 2.4.4) were immunostained with antibodies to 
GFP (which recognises CFP) and MBP.  Neuritic integrity and neurite density was 
assessed and quantified in minimum of three independent experiments (Chapter 
2.6.3). The integrity of CFP and non-CFP expressing neurites in an LPS-treated 
and PBS-treated culture was assessed following staining with an antibody (SMI31) 
against phosphorylated neurofilament (Chapter 2.5) 
  
4.2.4 Hydrogen peroxide (H2O2) treatment of cultures 
Myelinating cultures at 21 DIV (± 2 days) were treated with 100 mM of 30% 
hydrogen peroxide (H2O2) (Nikic et al., 2011) or PBS for 1 hour.  
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4.2.5 Statistical analysis 
Neuritic changes after incubation with the myelin-enriched tissue fraction (wild 
type and Plp1-transgenic) or LPS, in the presence or absence of myelin-laden 
microglia/macrophages, were analysed using one way ANOVA.  Comparisons 
between the myelin treated, LPS treated or both myelin and LPS treated 
cultures and the PBS treated controls were made using a Dunnett’s multiple 
comparison test.  Significance was set at p< 0.05. 
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4.3 Results 
4.3.1 Cyan fluorescent protein as a sensitive marker of neuritic 
integrity  
Yellow fluorescent protein (YFP), an analogue of GFP, is a very sensitive marker 
of axonal changes, in vivo (Bridge et al., 2007). To determine if CFP is a 
sensitive marker of neuritic integrity in vitro, cultures were immunostained with 
antibodies to CFP and to phosphorylated neurofilaments (SMI31). Both markers 
label neuronal processes, including axons.  
Comparison of double labelled cultures showed that CFP was only expressed in a 
subset of neuronal processes, allowing individual neurites to be visualised over 
long distances (Figure 12 A). In contrast, SMI31 labelled many more neurites, 
making identification of individual fibres (especially over a distance) difficult 
(Figure 12B). CFP is not expressed in the embryo and therefore the proportion of 
embryos that were CFP positive could not be determined. However, based on 
Mendelian genetics, on average 50% of embryos should express the transgene, 
which is expressed in a subset of neurons (Feng et al., 2000). 
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Figure 12:  Individual CFP positive neurites can be visualised over long 
distances.  Micrographs of a myelinating culture at 25 DIV stained with antibodies 
to (A) GFP (an analogue of CFP) and (B) SMI31 (a marker of phosphorylated 
neurofilament).  CFP is expressed in a subset of neurons only, allowing individual 
neurites to be visualised over long distances (arrows).  In contrast, neurofilament 
stained neurites are too densely packed to permit visualisation of individual 
fibres. Scale bar 50 µm  
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The expression of fluorescent proteins in neurons can subtly alter the neuron’s 
response to injury (Comley et al., 2011).  To confirm that CFP-rendered neurons 
are susceptible to injury in vitro, cultures were treated with H2O2, which has 
previously been shown to induce axonal injury in vivo (Nikic et al., 2011). In 
cultures treated with 100 mM H2O2 for 1 hour, neurites appeared (i) transected 
and (ii) developed numerous large focal swellings, or (iii) appeared fragmented, 
in some cases to the extent that individual neurites could not be discerned 
(Figure 13). This confirms that CFP expressing neurons are susceptible to injury 
and demonstrates that morphological changes in CFP positive neurites are a 
useful indicator of injury.  
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Figure 13:  CFP-rendered neurites are susceptible to injury.  At 22 DIV, cultures 
were treated with either (A) PBS or (B) 100 mM H2O2 for 1 hour then fixed and stained 
with an antibody to GFP (an analogue of CFP).  Cultures treated with H2O2 developed 
signs of neuritic injury including (i) transection (arrowheads) and (ii) large focal 
swellings (small white arrows) or (iii) fragmentation (small blue arrows) when 
compared to PBS treated controls.  Scale bar 50 µm.  
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Since putative microglial-mediated neuritic injury could potentially occur 
secondarily to oligodendroglial injury, it was important to determine if CFP 
positive neurites were myelination competent.  Double labelling of DIV 27 
cultures with antibodies to GFP and MBP showed that both non-myelinated and 
ensheathed/myelinated CFP positive neurites were present throughout the 
culture (Figure 14). 
Together, these results confirm that CFP expression in neurites provides a 
valuable tool for assessing neuritic injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4  90 
 
Figure 14:  CFP positive neurites are myelination competent in vitro.  Micrographs 
of cultures at 27 DIV stained with antibodies to (A) GFP (an analogue of CFP) or (B) 
myelin basic protein (MBP), showing both relatively mature (smooth) and immature 
(incomplete) sheaths.   (C) Overlay of images (A) and (B) shows co-localisation of GFP 
and MBP, indicating myelin-like sheaths around axons (arrows) demonstrating that the 
CFP expressing neurites are myelination competent.  Scale bar 50 µm.   
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4.3.2 Assessing neuritic integrity in cultures incubated with 
myelin debris 
To determine if myelin-laden microglia/macrophages elicit injury to neurites, 
neuritic changes were quantified in cultures treated for 1 or 7 days with 0.1 
mg/ml of either wild type or Plp1 transgenic myelin. Neurites were examined 
and characterised as (i) normal, (ii) beaded (small focal swellings <20 µm2 along 
otherwise intact neurites), (iii) degenerate/transected (fragmented or severed) 
or (iv) focally swollen but intact (swellings greater than 20 µm2) (Figure 15) and 
further characterised as myelinated/ensheathed or non-myelinated.  At DIV 28 
(±1 DIV) many CFP positive neurites, even in control cultures, appeared beaded 
suggesting that this morphological feature was not a useful marker of injury. 
Therefore only swollen or degenerating/transected neurites were considered to 
be injured. 
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Figure 15: CFP-rendered neurites indicating various categories of neuritic 
changes.  Micrographs of cultures at 27 DIV stained with antibodies to (A) GFP (an 
analogue of CFP) and (B) myelin basic protein (MBP), showing categories of neuritic 
changes synonymous with injury.  Neurites were categorised as myelinated 
(arrowhead) or non-myelinated (blue arrow) (C).  The neurites were then categorised 
by the degree of neuritic change, either beaded (swellings < 20 µm2; arrow), 
containing swellings (>20 µm2; *) or degenerating/transected (**). Bar 20 µm 
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At 28 (± 1) DIV in the presence of saturating amounts of myelin, in all treatment 
conditions and incubation times, a proportion (no more than 20 %) of neurites 
contained focal swellings >20 µm2, signs of transection or early indication of 
degeneration. However, there was no significant difference (p > 0.05) in the 
proportion of neurites containing changes in myelin or latex bead-treated 
cultures compared to PBS treated controls (Figure 16A and B). To test if neurite 
survival was altered in myelin-treated cultures, neuritic densities were 
quantified. Neuritic density also remained unaltered in myelin- or latex bead-
treated cultures compared to PBS-treated controls (Figure 16C and D) (p > 0.05).    
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Figure 16: Quantification of   neuritic changes and neuritic densities in myelin 
treated cultures compared to latex bead and PBS-treated controls.  Cultures were 
treated with 0.1 mg/ml of wild type or Plp1-tg myelin at 20 DIV for either 1 or 7 
days.  (A) and (B) Graphs indicating mean percentages of all neurites (+ s.e.m). 
After incubation with either wild type or Plp1-tg myelin for 1 or 7 days the 
percentage of all (myelinated and non-myelinated) CFP positve neurites which 
showed signs synonymous with injury, were quantified.   No statistically significant 
change was observed in the percentage of CFP positive neurites showing signs of 
swellings or degeneration in myelin or latex bead-treated cultures compared to PBS-
treated controls at either time point. (C) and (D) Graphs indicating mean neuritic 
numbers per AOI (+ s.e.m). Neuritic densities were similar in all culture conditions, 
and after both1 and 7 days of treatment, demonstrating that there was no loss of 
neurites in myelin or latex bead-treated cultures compared to PBS-treated controls. 
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4.3.3 The effects of lipopolysaccharide stimulation of myelin-
laden microglia/macrophages on neuritic integrity in vitro 
Since no evidence was obtained to support the suggestion that myelin-laden 
microglia/macrophages were axono-toxic, the putative neuro-protective/anti-
inflammatory effect of myelin-laden cells in an inflammatory environment, was 
assessed. Cultures were treated with PBS alone or with a saturating 
concentration of myelin debris for 3 DIV then stimulated for 48 hours with LPS.  
Previously, stimulation of microglia/macrophages with LPS resulted in 
morphological alterations associated with ‘activation’ of this population 
(Chapter 3.3.8).  Neuritic changes were not more prevalent in cultures 
stimulated with LPS, either with or withour myelin-laden microglia than in non-
LPS stimulated cultures (p>0.05) (Figure 17A). Neuritic density was also 
unchanged in LPS stimulated cultures compared to controls (p>0.05) (Figure 
17B).   
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Figure 17: Neuritic changes and neuritic densities were similar in LPS treated 
cultures in the presence or absence of myelin-laden microglia/macrophages to 
PBS-treated controls.  Cultures were treated with 0.1 mg/ml of wild type  myelin at 
20 DIV for 3 days until the microglia/macrophages developed a myelin-laden 
appearance and then treated with either LPS (100 ng/ml) or PBS for 48 hours.  (A) 
Graph indicating mean percentage (+ s.e.m.) of all CFP positive neurites manifesting 
changes. No statistically significant difference was observed in the percentage of CFP 
positive neurites showing signs of swellings or degeneration/transection in LPS 
treated cultures, with or without myelin-laden microglia, compared to PBS-treated 
controls.  (B). Graph showing mean neurite number (+ s.e.m.) per AOI. There was no 
statistically significant difference in neuritic density in LPS-treated cultures, with our 
without lipid-laden microglia, compared to PBS-treated controls.   
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To determine if myelinated neurites acquired neuritic changes secondarily to 
inflammatory-mediated injury to oligodendrocytes in the presence of LPS, 
number of myelinated neurites showing changes as a percentage of the total 
number of myelinated neurites was assessed in each experimental condition. The 
results demonstrated that there was no increase in the number of myelinated 
neurites manifesting signs of injury in the LPS-stimulated cultures (in the 
presence or absence of myelin-laden microglia/macrophages) compared to 
myelin only- or PBS only-treated controls (Figure 18) (p> 0.05).   
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Figure 18: LPS stimulation of microglia/macrophages did not lead to injury of 
myelinated axons  Cultures were treated with 0.1 mg/ml of wild type  myelin or 
with PBS at 20 DIV for 3 days then treated with either LPS (100 ng/ml) or PBS for 48 
hours.  Graph indicating mean percentage (+ s.e.m.) of all myelinated CFP positive 
neurites manifesting changes. No statistically significant difference was observed in 
the percentage of myelinated CFP positive neurites showing signs of swellings or 
degeneration/transection in LPS treated cultures, with or without myelin-laden 
microglia, compared to PBS-treated controls.   
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4.3.4 Response of CFP and non-CFP expressing neurites to LPS-
stimulation of microglia/macrophages. 
To assess if non-CFP expressing neurites were more vulnerable to microglial-
mediated induced injury after LPS stimulation, cultures were incubated with LPS 
for 48 hours and then immunostained with an antibody to GFP and with SMI31, 
which recognises phosphorylated neurofilament (Figure 19).  Quantification of 
the area occupied by SMI31 staining demonstrated that there was no reduction in 
SMI31 staining in the LPS-treated cultures compared to PBS-treated controls 
(Figure 20). Similarly, the density of CFP positive neurites was not altered in the 
LPS-treated cultures (Figure 20), as demonstrated above (4.3.2). The results of 
this single experiment suggest that non-CFP expressing neurites are not more 
vulnerable to LPS induced injury compare to CFP positive neurites. 
 
 
 
 
 
 
 
Chapter 4  101 
 
 
Figure 19:  Non-CFP expressing neurites are not more vulnerable to LPS induced 
injury than CFP-rendered neurites. Micrographs of cultures at 25 DIV treated with 
either (A) PBS or (B) LPS for 48 hours and then stained with antiboties to SMI31 or 
GFP (an analogue to CFP).  Both CFP and SMI31 staining show similar densities of 
neurites in the PBS and LPS treated cultures.  This indicated that non-CFP expressing 
neurons are not more vulnerable to LPS induced injury compared to CFP expressing 
neurons in vitro.  Scale bar 50 µm  
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Figure 20: Non-CFP expressing neurons are not more vulnerable to LPS induced 
injury than CFP-expressing neurons. Cultures at 20 DIV were treated with either LPS 
or PBS for 48 hours and then stained with antibody to neurofilament or GFP (an 
analogue of CFP).  Graphs showing (A) area occupied by neurofilament staining and 
(B) densities of CFP-rendered neurites.  
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4.4 Discussion 
Identification of the cellular and molecular effectors of neuritic injury is a key 
factor in developing potential treatments for neurodegenerative diseases.  One 
of the advantages of the in vitro system used in this thesis is that it comprises 
all neural cell types, that is, neurons, oligodendroglia and astroglia, as well as 
microglia. Therefore, the complex cellular interactions that occur in vivo are 
partially reproduced. Furthermore, in comparison to in vivo situations, the 
system can be manipulated readily, in order to address simple questions. Here, 
this system was used to determine if myelin-laden microglia/macrophages were 
either axono-toxic in a normal environment or axono-protective in an 
inflammatory environment.  
Several studies have shown that microglia/macrophages secrete pro-
inflammatory factors in response to the phagocytosis of myelin (Williams et al., 
1994;Mosley and Cuzner, 1996;van der Laan et al., 1996) including TNF-a, IL-1, 
IL-6 and soluble nitric oxide. Since factors such as TNFα or nitric oxide can 
injure neurites in vitro (Stagi et al., 2005;Stagi et al., 2006;De Vos et al., 2000) 
and in vivo (Smith et al., 2001) by disrupting axonal transport status, and agents 
that inhibit microglial action, for example Glatiramer acetate (GA) or 
minocycline, can protect against axonal injury (Gilgun-Sherki et al., 2003;Howell 
et al., 2010), it seemed reasonable to speculate that neuritic injury might 
represent a consequence of myelin phagocytosis. However, in the work 
described in this chapter, no evidence was obtained to support the suggestion 
that the phagocytosis of a myelin-rich tissue fraction drives 
microglia/macrophages to become axono-toxic. Due to the failure of LPS 
stimulated microglia/macrophages to induce injury, the putative protective 
effects could not be determined.  
The absence of increased neuritic injury in myelin-treated cultures is, in 
retrospect, perhaps not surprising. Microglia are part of the innate immune 
system whose primary role it is to protect from pathogens and remove debris 
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such as apoptotic cells and myelin debris (Napoli and Neumann, 2009). While 
there is evidence in the literature to support the suggestion that ‘activated’ 
microglia/macrophages elicit injury to neighbouring neural cells (Howell et al., 
2010;Lehnardt et al., 2003;Pang et al., 2010), it was recently demonstrated that 
microglia in the developing CNS that phagocytose apoptotic supernumerary 
neurons (McArthur et al., 2010), or respond to experimentally induced Wallerian 
degeneration (Palin et al., 2008) acquire an anti-inflammatory or ‘alternatively 
activated’ phenotype, respectively. 
Nonetheless the absence of increased neuritic injury in myelin treated cultures 
cannot be considered to provide conclusive evidence that myelin-laden 
microglia/macrophages do not injure neurites. For example, it is possible that 
this population secrete potentially injurious factors but that these become 
diluted out in the relatively large volume of medium in which the cells are 
grown. Furthermore, it is possible that direct contact between microglia and 
neurites does not take place in culture, limiting the potential of the cells to 
induce injury. These possibilities are addressed further in Chapter 5. 
To determine if myelin-laden microglia/macrophages protected neurites in an 
inflammatory environment, cultures containing myelin-laden cells were 
stimulated with LPS. LPS-stimulation act through expression of Toll-like receptor 
4 (TLR 4) expressed on the cell surface of microglia and leads to ‘activation’ and 
the production of inflammatory factors including TNF-α, IL-1β, IL-12p40 and IL-6 
(Nakamura et al., 1999;Boven et al., 2006;Glim et al., 2010). It has previously 
been shown that LPS stimulation of mixed neural cultures leads to extensive, 
microglial mediated neuronal death in vitro (Lehnardt et al., 2003). Surprisingly, 
LPS did not drive these intrinsic cells to induce neuritic injury, leaving the 
axono-protective effects of the myelin-laden microglia/macrophages yet to be 
determined.   
Due to this unexpected result, it was important to demonstrate that CFP 
expressing neurites were not resistant to inflammation-mediated injury 
compared to non-CFP positive neurites.  A study by (Comley et al., 2011)  
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examining the biological relevance of fluorescent proteins in vivo suggested that 
Thy1 driven fluorescent protein expression triggered multiple cell stress 
responses that subtly altered neuronal morphology and influenced the rate of 
neurodegeneration in experimental axonopathy.  Thus CFP positive neurites 
could potentially be resistant to injury because cellular stress responses are 
already triggered.  However, immunocytochemical analysis of LPS treated 
cultures showed that overall, neurites (including CFP positive and CFP negative) 
did not demonstrate more signs of injury in LPS treated cultures compared to 
PBS treated cultures.  Furthermore incubation of the cultures with 100 mM 
hydrogen peroxide treatment of the cultures demonstrated that CFP expressing 
neurites were vulnerable to reactive oxygen species-induced injury, which 
manifested as fragmentation, focal swelling and/or transection.    
Previous studies have shown that LPS stimulated microglia are detrimental to 
oligodendrocytes (Domercq et al., 2007) and their precursors (Pang et al., 2010) 
in vitro, suggesting that myelinated axons may be vulnerable to secondary 
damage as a consequence of primary injury to the oligodendrocyte.   However, 
myelinated neurites did not demonstrate increased susceptibility to injury in LPS 
treated cultures compared to PBS treated control cultures. Furthermore, the 
proportion of myelinated neurites that appeared injured was similar to the 
proportion of all neurites manifesting changes. 
The failure of LPS-stimulated microglia/macrophages to induce injury in the 
present study may be due to the fact that this population represents a small 
proportion of the total cell population in the myelinating cultures. In order to 
maintain the biosynthetically active cultures in optimal condition, they have to 
be cultured in a relatively large volume of medium. This could dilute out 
potentially injurious factors and result in reduced LPS-induced cytotoxicity. It 
has been demonstrated previously that extracellular KCl enhances LPS-induced 
cytotoxicity (Chang et al., 2000), resulting in the loss of neurons, 
oligodendrocytes and astrocytes in mixed neural cell cultures (Lehnardt et al., 
2003). It would be of interest to determine if KCl in addition to a similar or 
increased dose of LPS would be sufficient to cause LPS-induced neuritic injury, 
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thereby allowing the anti-inflammatory effects of the myelin-laden 
microglia/macrophages to be determined.  
(Perry, 2010) recently showed that in aged or diseased brain, microglia adapt a 
primed phenotype that makes them more susceptible to systematic infection and 
drives a more aggressive disease pathology.  It seems possible the microglia in 
myelinating cultures generated from wild type mice are not primed to drive a 
pathologically relevant response as a result of LPS stimulation.   
Conversely, CNS inflammation involves cross-talk between cells of both the 
innate and adaptive immune systems (Kerschensteiner et al., 2003).  Although 
myelin-laden or LPS-stimulated resident microglia may not be axono-toxic 
themselves, they have been shown to secrete pro-inflammatory cytokines or 
chemoattractants, when cultured in isolation (Williams et al., 1994;Mosley and 
Cuzner, 1996;van der Laan et al., 1996). In vivo, this would eventually 
encourage recruitment of T-cells from the periphery. Secondary T-cell responses 
have a pathogenically relevant impact on CNS axons (Ip et al., 2006) in a mouse 
model of a primary genetic defect in the oligodendrocyte.  Clearly, the 
myelinating cell culture system used in this study contains no cytotoxic T-cells.  
As the results of this chapter would suggest, the phagocytosis of myelin debris is 
not sufficient to ‘activate’ microglia/macrophages towards an axono-toxic 
phenotype.  Since neither an axono-toxic or axonal-protective phenotype could 
be identified for this population the reason for this will be assessed further in 
Chapter 5 in which the soluble cytokine/chemokine profile of myelin and LPS-
treated cultures is assessed.  
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5 The dynamic interaction between myelin-laden 
microglia/macrophages and neurites and 
secretion of soluble factors in vitro 
5.1 Introduction 
The overall aim of this study was to determine if the phagocytosis of myelin 
debris by microglia/macrophages would drive these cells towards either an 
axono-toxic or axono-protective phenotype.  The data presented in Chapter 4 
demonstrates that cultures containing myelin-laden microglia are not 
characterised by an increase in neuritic changes synonymous with injury.   
Potentially, microglia/macrophages could harm axons through contact mediated 
effects as suggested by the proximity and elevated numbers of microglia at sites 
of axonal injury in MS and in demyelinating models (Nikic et al., 2011;Edgar et 
al., 2010;Pohl et al., 2011).  Alternatively, injury could be elicited by secretion 
of pro-inflammatory cytokines and nitric oxide (van der Laan et al., 1996;Mosley 
and Cuzner, 1996;Williams et al., 1994;Jeon et al., 2008;Sun et al., 2010). Nitric 
oxide and TNF-α have been shown to cause injury to oligodendrocytes (Domercq 
et al., 2007), in particular to oligodentrocyte precursor cells (Pang et al., 2010). 
These factors have also been shown to impinge on axonal mitochondria (Haider 
et al., 2011) and obstruct axonal transport in vitro (Stagi et al., 2005;Stagi et 
al., 2006;De Vos et al., 2000).   
In relation to the putative axono-protective phenotype of microglia, these could 
not be determined in the work undertaken in the previous chapter because 
stimulation of microglia/macrophages by phagocytosis of myelin debris, did not 
result in neuritic injury (Chapter 4). Others have shown that myelin-laden 
microglia/macrophages secrete anti-inflammatory cytokines (Boven et al., 
2006;Liu et al., 2006) including IL-6 and IL-10 that ameliorate the effects of LPS-
induced stimulation of macrophages.   
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In light of the unanticipated results reported in Chapter 4, the overall aim of this 
chapter was to determine if the lack of injury could pertain to (i) absence of 
contact between microglia/macrophages and neurites or (ii) failure of 
microglia/macrophages in the myelinating culture system to secrete harmful 
cytokines/chemokines.  
The aims of this chapter were: 
1. To examine the physical interaction of phagocytic migroglia/macrophages 
and adjacent neurites  
2. Characterise the cytokine/chemokine profile of the myelin-treated cultures  
3. Determine if LPS stimulation initiated a pro-inflammatory response in this in 
vitro system and if this was ameliorated in the presence of myelin-laden 
microglia/macrophages.    
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5.2 Materials and methods 
5.2.1 Time-lapse imaging of myelinating cultures 
Time lapse imaging of cultures was undertaken over a period of 15 hours. Image 
capture started immediately after the addition of myelin to the culture (for 
further detail, see Chapter 2.7).  Images were taken on bright field (phase 
contrast), ‘cherry’ (rhodamine labelled myelin) and CFP/YFP (neurites) 
channels, from randomly selected areas using a 20x objective, with 5 minute 
intervals between frames.  For each area imaged, a composite movie was 
generated from the bright field and cherry channels.  
5.2.2 Proteome array analysis of culture medium collected from 
treated cultures  
Medium from the cultures analysed in Chapter 4 was collected and stored at -
80oC, then analysed using a proteome array panel (mouse cytokine array panel A 
kit from R&D systems, Abingdon) containing over 40 different anti-cytokine, 
anti-chemokine antibodies (see Appendix 2 for list of chemokines/cytokines 
tested) dotted in duplicate onto a nitrocellulose membrane (for further detail 
see Chapter 2.8). 
5.2.3 Quantification of cytokine/chemokine steady state levels 
Steady state levels of soluble cytokine/chemokines in conditioned culture 
medium were quantified from analysis of the signal volume of each array spot 
generated from scanned X-ray films, using array analysis software (TotalLab 
TL100 Array v2008; Newcastle upon Tyne). For each membrane (one membrane 
per experimental condition), the average signal volume of each of the 
cytokine/chemokine pairs was normalised to the average spot intensity of the 6 
positive control spots on each membrane. 
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5.2.4 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 5 software. 
Comparrisons between relative spot volumes of myelin or bead-treated cultures 
and PBS-treated controls were made using one way ANOVA followed by Dunnett’s 
multiple comparison post-test.  Significance was set at p < 0.05. 
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5.3 Results 
5.3.1 Physical interaction between myelin-laden 
microglia/macrophages and neurites 
Microglia/macrophages could potentially injure axons through physical contact 
or by the release of soluble factors. To determine whether there is physical 
contact between phagocytic myelin-laden microglia/macrophages and 
neighbouring neurites, cultures were incubated with rhodamine-labelled myelin 
debris and imaged using time-lapse microscopy.  
Time-lapse microscopy (see attached CD) demonstrated that phagocytic 
microglia/macrophages were highly motile and made physical contact with 
neighbouring neurites (Figure 21). In some cases the microglia/macrophages 
appeared to ‘pluck’ the neuritic bundles, physically relocating them (as 
illustrated in the stills in Figures 21 C-G), as they phagocytosed the surrounding 
myelin debris (Figure 21 D-L).   
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Figure 21:  Time lapse imaging of rhodamine-labelled myelin fraction treated 
culture showing physical contact between microglia/macrophages and 
neighbouring neurites.  Time lapse stills over 1130 minutes showing phagocytosis of 
labelled myelin fraction (red).  Images show labelled myelin debris at time of 
addition (A-C) and then being phagocytosed by endogenous microglia/macrophages 
(D-L). Images (C-G) show the physical interaction between microglia/macrophages 
and neighbouring neurites.  Neurites are physically ‘plucked’ (arrows) by 
microglia/macrophages as they survey for surrounding myelin debris.  Scale bar 50 
µm. 
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5.3.2 Proteome array analysis of culture medium from myelin 
treated cultures 1 and 7 days post treatment 
To examine the array of soluble factors secreted by the phagocytic 
microglia/macrophages in response to myelin debris, proteome array analysis 
was carried out on medium collected from the myelin treated cultures. 
Visual examination of the cytokine/chemokine profile of the myelin treated 
cultures suggested that the steady state levels of soluble cytokines/chemokines 
was similar in cultures treated with wild type or Plp1 transgenic myelin, or with 
latex beads, compared to PBS-treated controls at 1 day post-treatment (Figure 
22 A-D). In cultures treated for 7days, the results tended to be more variable 
with a number of cyokines/chemokines appearing up- or down-regulated in the 
myelin-treated cultures compared to controls (a typical result is illustrated in 
Figure 22 E-H). 
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Figure 22: Proteome array analysis of media collected from myelin treated 
cultures. Typical profiles from cultures 1 (A-D) or 7 (E-H) days post incubation with 
either PBS, latex beads or 0.1 mg/ml wild type of Plp1 transgenic myelin debris. 
Culture medium was tested with antibodies to 40 different cytokines/chemokines, 
spotted in duplicate on a nitrocellulose membrane. Normalising each pair of 
chemokines/cytokines to the 6 positive controls (white boxes) within each 
membrane, there was no visible difference in profiles obtained from myelin-treated 
cultures compared to latex bead or PBS-treated cultures 1 day post treatment. In 
cultures treated for 7 days there was a tendency for more variation, however this was 
not consistent when examined across 3 independent experiments.  
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Semi-quantitative analysis of two independent cultures incubated with myelin 
for 1 DIV, demonstrated a tendency for a transient reduction in interleukin 1 
receptor antagonist (IL-1ra) in the myelin-treated cultures compared to PBS and 
latex bead-treated cultures (Figure 23A).  Aside from this, no other of the 40 
cytokines/chemokines tested, including pro- and anti-inflammatory facts 
previously shown to be up- or down-regulated in response to the phagocytosis of 
myelin, demonstrated any consistent alteration (Figure 23 B-C). 
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Figure 23: Cytokine/chemokine profiles from cultures incubated with myelin 
debris for 1 day. Medium from cultures treated with either wild type or Plp1-
transgenic myelin, latex beads or PBS for 1 day, was analysed using a proteome array 
containing antibodies to 40 different cytokines/chemokines. (A, B and C) Graphs 
showing results of semi-quantitative analysis of relative levels (mean + s.e.m.) 
showed a consistent reduction in IL-1ra (see graph A) in cultures treated with myelin 
debris compared to latex bead- or PBS-treated controls. However, there was no other 
consistent alteration in the levels of any of the soluble factors tested (n=2). 
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Semi-quantitative analysis of three independent cultures incubated with myelin 
for 7 DIV demonstrated a tendency for chemokines  KC, macrophage colony 
stimulating factor (M-CSF), macrophage inflammatory protein 1α (MIP-1α) and 
MIP-1β to be slightly, but not significantly, up regulated in the myelin treated 
cultures compared to latex bead-treated and PBS- treated controls (Figure 24 B).  
This was also true for IP-10 (alternative nomenclature CXCL10) and RANTES, in 
the Plp1-transgenic myelin-treated cultures compared to all other conditions 
(Figure 24 B).  Steady state levels of sICAM1 was significantly (p < 0.001) 
elevated in wild type and in Plp1 transgenic myelin-treated cultures compared 
to latex bead or PBS-treated controls (Figure 24 C).    
Most cytokines including the interleukin family members, IL-1, IL-2, IL-6 and IL-
12, were less than 10 % of the control spot values in the profiles from either the 
myelin- or latex bead-treated cultures or the PBS-treated controls after either 1 
or 7 day incubations (Figure 23 A and 24A).  
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Figure 24: Cytokines/chemokines profiles from cultures incubated with myelin 
debris for 7 days. Medium from cultures treated with either wild type or Plp1-
transgenic myelin, latex beads or PBS for 1 day was analysed using a proteome array 
containing antibodies to 40 different cytokines/chemokines. (A, B and C) Graphs 
showing results of semi-quantitative analysis of relative levels (mean + s.e.m.) showed 
no significant alteration of cytokines in myelin treated cultures compared to latex 
bead or PBS-treated controls. A tendency for up-regulation of certain chemokines 
including significant up-regulation of sICAM-1 (see graph B) was observed in the 
myelin-treated cultures compared to controls. Stars indicate p values: ***p < 0.001. 
There was no other consistent alteration in the levels of any of the soluble factors 
analysed (n=3). 
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5.3.3 Proteome array analysis of culture medium collected from 
myelin-laden microglia/macrophages in response to 
lipopolysaccaride treatment 
No increase in neuritic changes synonymous with injury were observed in 
response to treatment with LPS (see section 4.3.3 Chapter 4). To determine the 
cytokine/chemokines profile of LPS stimulated cultures culture medium was 
collected from LPS treated cultures in the presence or absence of myelin-laden 
microglia.  
Proteome array analysis of two independent experiments, showed there was an 
up-regulation of inflammatory cytokines in the LPS-treated cultures for example 
IL-1α, IL-1β, IL-6, and TNF-α, compared to PBS-treated controls (Figure 25).  
From the profiles obtained, this inflammatory response did not appear altered 
by the presence of myelin-laden microglia/macrophages (Figure 25 C).  This was 
confirmed by semi-quantitative analyses of cytokine/chemokine levels, which 
showed that there was no marked change in steady-state levels of 
cytokines/chemokines in myelin-treated cultures compared to PBS-treated 
controls, after LPS stimulation (Figure 26 A-C). 
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Figure 25:  Proteome array analysis of media collected from LPS treated cultures in 
the presence or absence of myelin-laden microglia/macrophages.  Medium was 
collected from cultures at 26 DIV (± 1 DIV) treated with either (A) PBS, (B) LPS for 48 
hours or (C) LPS after treatment with 0.1 mg/ml myelin debris for 3 DIV until the 
microglia/macrophages became myelin-laden.  After treatment with LPS there was 
obvious up-regulation of key inflammatory cytokines including TNF-α (orange box), IL-
1α, IL-1β (green box) and IL-6 (blue box), which did not appear ameliorated by the 
presence of myelin-laden microglia/macrophages.  
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Figure 26: Cytokine/chemokine profiles from cultures stimulated with LPS in the 
presence or absence of myelin-laden microglia/macrophages. Medium from cultures 
pre-treated for 3 days with either PBS or myelin debris and then stimulated with LPS 
for 48 hours was analysed using a proteome array containing antibodies to 40 different 
cytokines/chemokines. (A, B and C) Graphs showing results of semi-quantitative 
analysis of relative levels (mean + s.e.m.) showed no amelioration of LPS induced 
cytokine/chemokine release in the presence of myelin-laden microglia/macrophages. 
(n=2). 
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5.4 Discussion 
As previously discussed, identifying the cellular effectors that are responsible for 
neuritic injury is key to understanding the process of axonal loss in inflammatory 
diseases.  Using an in vitro myelinating culture system to examine the putative 
role of the phagocytic microglia in neuritic injury, it was demonstrated that, at 
least within the myelinating culture system used in this study, the phagocytosis 
of myelin debris was not sufficient to drive these cells towards an axon-toxic 
phenotype.  In this chapter, the physical interaction between 
microglia/macrophages and neurites, and the soluble cytokine/chemokine 
profiles of the cultures were examined.  
The failure of the microglia/macrophages to elicit neuritic injury, as 
demonstrated in Chapter 4, supports the conclusion that myelin-laden microglia/ 
macrophages are not axono-toxic. In vivo, axons are tightly intertwined with the 
processes of macro- and microglial cell and the failure of the 
microglia/macrophages to elicit neuritic injury in vitro could potentially be due 
to a lack of physical contact between microglia/macrophages and neurites. 
However, time-lapse microscopy of the cultures showed that the highly motile 
phagocytic cells make physical contact with neurites.  Within 5 minutes of 
adding an exogenous myelin tissue fraction to the cultures, the intrinsic 
microglial/macrophage population began to phagocytose the debris and in doing 
so, physically contacted adjacent neurites, pulling them action in various 
directions from their initial trajectory.  Therefore it can be concluded that the 
absence of neuritic injury is not due to the absence of contact between 
microglia/macrophages and neurites.  
Neuritic injury in vivo could be induced by soluble factors secreted by 
‘activated’ microglia.  It has previously been documented that 
microglia/macrophages secrete harmful inflammatory factors including TNF-α, 
IL-1α, IL-1β or IL-6 in response to the phagocytosis of myelin debris (van der 
Laan et al., 1996;Mosley and Cuzner, 1996;Williams et al., 1994). In particular, 
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TNF-α  and soluble nitric oxide have been shown to injure axons in vitro (Stagi et 
al., 2005;Stagi et al., 2006;De Vos et al., 2000) and in vivo (Smith et al., 2001) 
by interrupting axonal transport of synaptic vesicle precursors, in particular, 
synaptophysin (Stagi et al., 2005;Stagi et al., 2006) and causing early stage 
anterograde degeneration in conducting axons (Smith et al., 2001). However, in 
the current study no up-regulation of key inflammatory cytokines such as TNF-α, 
IL-1α, IL-1β or IL-6, in response to the addition of myelin was observed. Due to 
the time constraints of the project, the levels of soluble nitric oxide secreted by 
the myelin-laden microglia/macrophages in this culture system remains to be 
assessed.  However, one could speculate that because there was no increase in 
neuritc changes (see Chapter 4) in the myelin-treated cultures compared to 
controls, the levels of nitric oxide would remain comparable between the 
myelin-treated cultures and controls.   
The differences between the findings of the current study and the 
aforementioned studies could be a result of the different systems used. For 
example (van der Laan et al., 1996;Mosley and Cuzner, 1996) added  opsonised 
rat myelin to macrophage-enriched rat cultures and (Williams et al., 1994) 
treated microglial-enriched human cell cultures with myelin from human CNS. In 
contrast, the current study was undertaken using a mixed murine neural cell 
culture, to which non-opsonised myelin was added.  However, opsonisation was 
previously shown not to influence the cytokine profile (van der Laan et al., 
1996), therefore, as discussed below, the differences could be due to the nature 
of the cells used and the multiple-cell type interactions that occur in the system 
used in the present study. 
In agreement with an earlier study (van et al., 2010), steady state levels of 
certain chemokines, such as MIP-1α, MIP-1β, MIP-2 and RANTES, had a tendency 
to be elevated in myelin-treated cultures compared to controls, after 7 days of 
incubation, although the differences were not significant.  It is difficult to draw 
any definitive conclusions from these results as the slight elevation in the levels 
of MIP-1α, MIP-1β, MIP-2 and RANTES was not consistent across all experiments.  
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In the current study there was significant up-regulation of the soluble inter-
cellular adhesion molecule 1 (sICAM-1) in the myelin-treated cultures compared 
to controls. sICAM-1 facilitates transmigration of leukocytes into tissues.  
Together, the results of the cytokine/chemokine array analyses suggest that the 
phagocytosis of myelin debris by microglia/macrophages in the myelinating 
culture system does not drive a pro-inflammatory phenotype but could confer a 
phenotype that facilitates recruitment of peripheral monocytes and T- 
lymphocytes. 
In vitro, monocyte recruitment is not possible, but in vivo, recruited monocytes 
could drive pathogenesis by stimulating microglia/macrophages to adapt a pro-
inflammatory phenotype (Hanisch and Kettenmann, 2007) or act themselves 
directly in a contact mediated fashion or through secretion of soluble factors to 
injure axons (Medana et al., 2001). The pathogenically relevant influence of T-
lymphocytes in genetically determined demyelinating disease models has been 
demonstrated using RAG null mice, in which the lack of mature lymphocytes led 
to a reduction in the numbers of CD11b positive cells and a significant 
amelioration of pathological changes, including axonal injury ((Ip et al., 2006).     
Several groups have demonstrated that LPS-mediated stimulation of 
microglia/macrophages in vitro results in the production of inflammatory 
cytokines and nitric oxide (Nakamura et al., 1999;Boven et al., 2006;Glim et al., 
2010).  In Chapter 3, an obvious morphological change in microglia/macrophages 
in response to LPS stimulation, was demonstrated.  A visual comparison of 
proteome arrays of medium from LPS-treated cultures compared to PBS-treated 
controls demonstrated a clear up-regulation of key inflammatory cytokines 
including IL-1α, IL-1β, IL-6 and TNF-α, indicating that cells in the culture system 
were susceptible to stimulation by LPS.  However, this difference requires final 
quantification. 
In contrast to a previous study that showed that the phagocytosis of myelin 
debris drives microglia/macropahges to adapt an anti-inflammatory phenotype 
that can ameliorate the effects of LPS-induced stimulation (Boven et al., 2006), 
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the results of the current study found no evidence for an anti-inflammatory 
phenotype. This is demonstrated by the lack of reduction in the secretion of pro-
inflammatory cytokines in cultures stimulated with LPS, in the presence of 
myelin-laden microglia/macrophages.  In contrast to the enriched macrophage 
system employed by (Boven et al., 2006), in the mixed cell culture system used 
here, astrocytes, which also express TLR4 in vitro, will also become activated in 
response to LPS (Bowman et al., 2003). Indeed the absence of IL-12 
upregulation, reflects the cytokine profile of activated mouse astrocytes which 
do not secrete IL-12 after stimulation. In contrast, microglia secrete both IL-12 
p35 and p75 after stimulation with IFN-γ/LPS in isolated cell cultures (Aloisi et 
al., 1997).  Therefore, the activated astrocytes could possibly contribute to the 
inflammatory response (Bowman et al., 2003) masking any down-regulation in 
secretion by microglia/macrophages after phagocytosis of myelin debris. 
Further, the secretion of IL-10 by astrocytes could down-regulate the secretion 
the inflammatory cytokines IL-12 p35 and p75 by microglia in a regulatory 
manner as has been previously shown in IFN-gamma/LPS stimulated mouse 
astrocyte/microglia co-cultures (Aloisi et al., 1997).  
The lack of shift in microglia/macrophage cytokine/chemokine profiles in 
response to myelin phagocytosis may reflect the fact that the cells are in a more 
physiologically relevant environment in comparison to cells cultured in isolation, 
in which neuro-immune cross-talk is inevitably absent and is in keeping with the 
observation of Glim et al (2010). 
However, the possibility that changes in cytokine/chemokine profiles are masked 
in the system used in this study cannot be excluded. Although densities of 
microglia/macrophages in the myelinating culture system (~400,000 cells/mm2) 
are similar to that in a 10 µm thick tissue section of murine white matter, the 
relative volume of medium in which the cultures are grown is much greater than 
the volume occupied by extracellular fluid in the CNS.  This will inevitably result 
in a dilution of secreted cytokine/chemokines.   
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Therefore, it is impossible to exclude the possibility that in a lower volume of 
medium, a significant shift in these secreted chemokines/cytokines compared to 
controls could potentially arise. Culturing the cells in a smaller volume of 
medium would concentrate the levels of secreted chemokines/cytokines, 
potentially unmasking changes that were undetectible in the current study.  
However, the cultures which are biosynthetically active (producing myelin 
membrane), grow optimally in the volume of medium used in the present study. 
Preliminary experiments using a more sensitive array system and smaller volume 
of medium also failed to show an increase in the levels of secreted 
chemokines/cytokines in myelin or LPS treated cultures, therefore suggesting 
potential changes were not being masked.   
In conclusion, the phagocytosis of myelin debris by this intrinsic 
microglia/macrophage population, in the culture system used here, did not drive 
these cells towards an axono-toxic phenotype. Neither did it lead to up-
regulation of inflammatory cytokines. The data provide no support for the 
suggestion that myelin-laden  microglia/macrophages are axono-toxic. The 
results of this chapter and Chapters 3 and 4 are considered together and 
discussed in Chapter 6. 
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6 Final Discussion and Future Studies  
The main purpose of this study was to determine if the phagocytosis of myelin 
debris per se was sufficient to drive microglia towards an axono-toxic 
phenotype, or alternatively towards an axono-protective phenotype which would 
protect adjacent axons in a pro-inflammatory environment. The results of this 
study show that neither saturating levels of myelin debris (including 
biochemically abnormal Plp1-tg myelin) and/or its phagocytosis were sufficient 
to drive the phagocytic cells to elicit neuritic injury. Axonal protection could not 
be determined. 
The work was carried out using a myelinating culture system. Characterisation of 
the intrinsic microglia/macrophages within the culture system showed that they 
were able to phagocytose exogenous myelin debris. However, this was not 
associated with a quantifiable change in cellular morphology, cell size or cell 
density. Although the expression of cell surface receptors on microglia in the 
culture system remains to be examined, the lack of overt signs of activation or 
increase in neuritc changes prompted an examination of steady-state levels of 
soluble factor within myelin treated cultures to determine if pro- or anti-
inflammatory cytokines were present. The results showed no shift towards either 
a pro- or an anti-inflammatory phonotype at the time points tested, either 1 or 7 
days post incubation with myelin debris. However, a transient change in 
cytokines/chemokines levels within shorter or intermediate time intervals 
cannot be excluded (discussed below).  
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6.1 The myelinating culture system as a tool for 
investigating the influence of myelin phagocytosis 
and axonal integrity  
The myelinating culture system used in these studies had several specific 
advantages over other experimental systems. First, in comparison to isolated 
microglia/macrophages (Williams et al., 1994;Boven et al., 2006;Mosley and 
Cuzner, 1996;van der Laan et al., 1996), the system contains most (though not 
all) of the cells that are present in the CNS in vivo. This permits many of the 
cell-cell interactions that occur in vivo to take place.  
For example, activated astrocytes have been shown to influence microglia in 
mixed cortical neuron/glia rat cultures through elevated expression of RANTES. 
This resulted in activation of the adjacent microglial population as evidenced by 
morphological changes, and increased numbers of MHC I- MHC II and IL-6 positive 
microglia cells in vitro (Ovanesov et al., 2008).  The activation of microglia may 
also impact downstream on other cell populations including oligodendrocytes 
(Pang et al., 2010) and adjacent neurites (Howell et al., 2010).  Although, the 
results of the current study showed that LPS-stimulated microglia did not prove 
deleterious to oligodendrocytes (based on the presence of myelinated axons) or 
to axons in the myelinating culture system, a previous study by (Pang et al., 
2010) has shown that LPS-activated microglia, in OPC-microglia co-cultures, 
impedes the oligodendrocytes lineage progression of OPCs, resulting in a 
reduction in MBP production.  Furthermore, it has been demonstrated in vivo 
using EAE models of chronic MS, that sites of paranodal axoglial disruption and of 
acute axonal injury correlated with local microglial inflammation, that was 
independent of demyelination or lymphocyte infiltration (Howell et al., 2010).   
Secondly, in contrast to in vivo systems such as that used by (Howell et al., 
2010) and colleagues, the myelinating culture system can be used to address the 
very specific effect of the presence of myelin debris, per se. In order to address 
the same question in vivo, myelin debris would have to be injected directly into 
the CNS, inevitably breaching the blood brain barrier, or through the induction 
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of demyelination by chemical or genetic means (Skripuletz et al., 2010;Linington 
et al., 1988;Bradl and Linington, 1996;Nikodemova et al., 2010;Pohl et al., 
2011), which would inevitably induce collateral damage, and confound the 
interpretation of the results.  
Thirdly, the myelinating culture system is a ‘closed-system’ that does not 
contain recruited monocytes/macrophages, therefore results can be interpreted 
in relation to the endogenous microglial population. 
However, one disadvantage of the system used in the current study, is that LPS 
stimulates other cell types, including astrocytes, through TLR4 (Bowman et al., 
2003) as discussed in Chapter 5. This stimulation of the astrocytes may cause a 
secretion of chemokines/cytokines that could potentially mask any influence of 
the microglia/macrophages after phagocytosis of myelin debris.  
  
6.2 The effects of myelin-laden microglia/macrophages 
on neurites in vitro 
The results of this study failed to demonstrate neuritic injury in response the 
addition of either myelin or LPS to the cultures. However these results must be 
interpreted with some caution. First, although there was no increase in neuritic 
changes at the time points tested, the presence of transient neuritic changes 
within just a few hours of treatment or at intermediate time points (i.e after 2, 
3, or 4 days) which resolve (Kerschensteiner et al., 2005) cannot be excluded. 
Secondly, as discussed in Chapter 5, soluble factors that could potentially harm 
axons may be present in insufficient quantities to induce neuritic injury, due to 
a dilutional effect. However, preliminary data obtained using a more sensitive 
Luminex system (Merck Millipore, Dundee) revealed similar results to the 
proteome profiles.   Excluding these caveats, the data fail to support the initial 
hypothesis that myelin-laden microglia are axono-toxic.  
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In demyelinating situations in vivo, signalling between injured oligodendrocyte 
and microglia/macrophages may be responsible for altering the status of the 
cells, thus rendering them harmful to axons. For example, cross-talk between 
oligodendrocytes harbouring a genetic mutation such as in the Plp1-transgenic 
mouse (Anderson, 1997) or those injured after exposure to infections, toxins or 
in instances of autoimmune disease such as those which occur in MS, may 
influence the phenotype of the microglia causing them to become axono-toxic or 
to recruit peripheral monocytes that drive forward the pathogenesis of disease.  
In the context of genetically determined or immune mediated demyelination, 
recruited cells (macrophages or T-cells) may be responsible for axonal injury. 
Indeed, T-cells can injure axons in vitro (Medana et al., 2001) and recruited CD8 
+ve T-lymphocytes has been shown to have a pathogenically relevant action in 
myelin injury and also in axonal injury in a mouse model of PMD (Ip et al., 2006).  
The secretion of chemokines by microglia that phagocytose myelin debris could 
recruit T cells under some circumstances. In the current study the presence of 
chemokines; MIP-1α, MIP-1β, RANTES and sICAM-1 revealed a tendency to be up-
regulated in the myelin-treated cultures compared to latex bead or PBS –treated 
controls. These particular chemokines are known chemoattractants involved in 
monocyte chemotaxis (Uguccioni et al., 1995)    
6.3 Future experiments 
In the current study it was shown that the phagocytosis of myelin debris was not 
sufficient to cause morphological changes synonymous with activation. However, 
changes in morphology do not always correlate with a shift in cellular phenotype 
(Schenk et al., 1999). Even in the absence of a change in cellular morphology, 
microglia could still shift phenotype by the up-regulation/presentation of 
surface antigen receptors (Block et al., 2007)) and FcR, specifically FCγRIII or 
FCγRIV which are expressed on ‘activated’ microglia (Lunnon et al., 2011) as 
well as, CD86 which is expressed on by APCs (Bauer et al., 1994).  
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In order to assess if moncocyte/macrophages recruited to sites of active 
demyelination are responsible for axonal injury in the context of myelin debris, 
the experimental protocol would have to be undertaken in vivo, for example by 
injecting myelin directly into the corpus callosum. Nevertheless, injection into 
the CNS involves breaching both the blood-brain barrier and CNS tissue which, in 
itself, would lead to local inflammation and a degree of leukocyte infiltration. 
This would have to be taken into consideration when designing control 
experiments and in interpretation of results.  
Even previous studies using other non-invasive models such as the cuprizone 
toxic demyelinating model, have shown a degree of local inflammation at sites 
of mass demyelination post treatment (Lindner et al., 2009;Matsushima and 
Morell, 2001). With this in mind, it appears that is difficult to find an ideal 
system to ask such a specific question such as the one addressed in this study.  
As there was no change in the pro- or anti-inflammatory profile in the myelin 
treated cultures compared to controls, future studies could focus on assessing 
the effects of adding either (i) enriched ‘activated’ myelin-laden 
microglia/macrophges or (ii) their conditioned medium, directly to the 
myelinating cultures to determine if this could result in neuritc injury or be 
protective in a pro-inflammatory environment. This would overcome the 
dilutional effects that may have contributed to the results obtained in the 
current study. However, this scenario is far from mimicking what would occur in 
vivo and the relevance requires consideration.     
A somewhat more realistic scenario, and one which is more relevant to MS, 
would involve stimulating the cultures with IFN-γ, which is a predominant pro-
inflammatory cytokine associated with MS. IFN-γ is secreted in response to Th1 
cell differentiation resulting in the activation of the downstream innate immune 
cells (Satoh and Kuroda, 2001;Panitch et al., 1987). Earlier studies investigating 
the potential of IFN-γ as a treatment for MS have shown that treatment with low 
dose IFN-γ exacerbates symptoms in patients with relapsing-remitting forms of 
MS (Satoh and Kuroda, 2001;Panitch et al., 1987).  
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6.4 Conclusion 
From the results of this in vitro study investigating the role of 
microglia/macrophage on neuritic damage, in the context of demyelination, I 
can conclude, that within this myelinating culture system, the presence of 
saturating myelin debris and/or its phagocytosis is not sufficient to drive the 
intrinsic microglia/macrophage population towards an axono-toxic phenotype. 
Due to the unexpected results of the LPS treated cultures, the axono- protective 
effects of the myelin-laden microglia/macrophages are yet to be determined. 
The findings of this investigation suggest that phagocytic microglia in a relatively 
physiological environment (versus in isolation) possess a quiescent phenotype in 
the context of myelin debris. With the functions of microglia/macrophages 
having already been outlined, the results of this study are perhaps not so 
surprising.  Since the primary role of the innate immune system is to protect the 
CNS, it would seem a terrible evolutionary design if the cells that are meant to 
protect us actually proved to be detrimental in their role. 
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7 Appendix 1 
 
7.1 Buffers 
 
7.1.1 Tris acetate EDTA buffer x10 (TAE buffer) 
48.4g Tris base (Fisher Scientific) 
11.4 ml Glacial acetic acid (Fisher Scientific) 
20 ml 0.5 M EDTA (Sigma-Aldrich) 
 made up to 1L with distilled water 
 
7.1.2 Phosphate buffer saline (PBS) 
8 g Sodium Chloride (Sigma-Alderich) 
1.44 g Disodium phosphate (Sigma-Alderich) 
0.24 g potassium dihydrogen (Fisher Scientific) 
0.2 g potassium chloride (Fisher Scientific) 
Dissolved in 800 ml of distilled water, adjusted to pH 7.4 with 1 M HCl (Fisher 
Scientific) and then made up to 1 L with distilled water 
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7.1.3 Towbin transfer buffers 
7.1.3.1 Anode 1 
36 g Tris (Fisher Scientific) 
74 ml Methanol (Fisher Scientific) 
Make up to 1 l in distilled water 
 
7.1.3.2 Anode 2 
3 g Tris (Fisher Scientific) 
75 ml Methanol (Fisher Scientific) 
Make up to 1 l with distilled water 
 
7.1.3.3 Cathode  
3 g Glycine (Sigma-Alderich) 
3 g Tris (Fisher Scientific) 
74 ml Methanol (Fisher Scientific) 
made up to 1 L  using distilled water 
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7.1.4 Ponceau S 
0.1% Ponceau S powder (Sigma-Alderich) 
1% glacial acid (Fisher Scientific) 
 made up to 1 L in distilled water) 
 
7.1.5 Tris buffer saline Tween (10 x) 
12 g Tris base (Fisher Scientific) 
87 g sodium chloride (Sigma-Alderich) 
10 ml Tween (Sigma-Alderich) 
Make up to 800 ml with distilled water and adjust to pH 7.4 with 1 M HCl top up 
to 1 L with more distilled water. 
 
7.1.6 5 X SDS/DTT denaturing buffer 
Bromophenol blue (0.25%)  
DTT (dithiothreitol; 0.5 M)  
Glycerol (50%) 
SDS (sodium dodecyl sulfate; 10%)  
Tris base (0.25 M, pH 6.8) (Fisher Scientific) 
Advanced Search 
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7.2 Myelinating cell culture 
7.2.1 Soyabean trypsin inhibitor and DNAase solution 
Soyabean trypsin inhibator (0.52 mg/ml, Sigma-Alderich) 
Bovine serum albumin factor V (3 mg/ml, Sigma-Alderich) 
DNAase (0.04 mg/ml, Sigma-Alderich) added immediately prior to addition to 
cell suspension 
made up in 1X Lebovitz medium 15 (L-15) (Gibco, Invitroge, Paisley) 
 
7.2.2 Plating medium 
50% 1X DMEM (Gibco, Invitrogen, Paisley) 
25% heat inactivated horse serum (Invitrogen, Paisley) 
23% 1X HBSS with Mg2+ and Ca2+ (Gibco, Invitrogen, Paisley)  
2% glutamine (Sigma-Alderich) 
 
7.2.3 Differentiation medium 
Final concentrations of differentiation medium ingredients are as follows: 
1X DMEM (Gibco, Invitrogen, Paisley) with penicillin (100U/ml)/streptomycin 
(100µg/ml) (Gibco, Invitrogen, Paisley)  
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Glucose (4.500mg/L, Sigma-Alderich) 
Hydrocortisone (50 nmols/ml, Sigma-Alderich) 
N1 hormone mix (0.5%)(see 7.2.4)  
Insulin (0.01mg/ml, Sigma-Alderich) 
Biotin (10ng/ml, (Sigma-Alderich) 
  
7.2.4 N1 hormone mix 
Final concentrations of N1 hormone mix ingredients are as follows: 
Apo-transferrin (1 mg/ml, Sigma-Aldrich) 
Putrescine (20 mM, Sigma-Aldrich) 
Progesterone (4 µM, Sigma-Aldrich) 
Sodium selenate (6 µM, Sigma-Aldrich)  
 
7.3 Tissue fixation 
7.3.1 Periodate-lysine-paraformaldehyde fixative (P-L-P) 
Immediately prior to use the buffered lysine solution (below) was added to 10% 
paraformaldehyde and the solution was then made up to 1 L using 0.1 M 
phosphate buffer. Finally, 2.14 g of sodium periodate was dissolved in the 
solution directly before use.  
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7.3.2 Buffered lysine solution  
13.7 g lysine monohydrate (Sigma-Aldrich) dissolved in 375 ml of distilled water 
1.8 g sodium hydrogen phosphate (Fisher Scientific) dissolved in 100 ml distilled 
water 
Solutions were then mixed together and pHd to pH 7.4 
 
7.3.4  10% paraformaldehyde  
20 g paraformaldehyde (Fisher Scientific) dissolved in 200 ml of distilled water 
and heated to 65 ºC using a few drops of 1 M NaOH were added to clear. The 
solution was then allowed to clear and was filtered through qualitative filter 
paper (Starlab).  
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8 Appendix 2 
8.1 Proteome array cytokine/chemokine list 
1. BLC    28. M-CSF 
2. C5a    29. JE  
3. G-CSF    30. MCP-5 
4. GM-CSF   31. MIG 
5. I-309    32. MIP-1α 
6. Eotaxin   33. MIP-1β 
7. sICAM-1   34. MIP-2 
8. IFN-γ    35. RANTES  
9. IL1-α    36. SDF-1 
10. IL-1β    37. TARC  
11. IL-1ra    38. TIMP-1 
12. IL-2    39. TNF-α 
13. IL-3    40. TREM-1 
14. IL-4 
15. IL-5 
16. IL-6 
17. IL-7 
18. IL-10 
19. IL-13 
20. IL-12 p70 
21. IL-16  
22. IL-17 
23. IL-23 
24. IL-27 
25. IP-10 
26. I-TAC 
27. KC 
143 
9 Reference list 
 
 
Alcázar A, Regidor I, Masjuan J, Salinas M, Alvarez-Cermeño JC (2000) Axonal 
damage induced by cerebrospinal fluid from patients with relapsing-remitting 
multiple sclerosis. J Neuroimmunol 104:58-67. 
Aloisi F (2001) Immune function of microglia. Glia 36:165-179. 
Aloisi F, Penna G, Cerase J, Menendez IB, Adorini L (1997) IL-12 production by 
central nervous system microglia is inhibited by astrocytes. J Immunol 159:1604-
1612. 
Anderson TJ (1997) Effects of increased dosage of the Plp gene: a study in 
transgenic mice. University of Glasgow. 
Arnett HA, Hellendall RP, Matsushima GK, Suzuki K, Laubach VE, Sherman P, 
Ting JP (2002) The protective role of nitric oxide in a neurotoxicant-induced 
demyelinating model. J Immunol 168:427-433. 
Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JPY (2001) TNFα 
promotes proliferation of oligodendrocyte progenitors and remyelination. Nat 
Neurosci 4:1116-1122. 
Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP (2003) Functional genomic 
analysis of remyelination reveals importance of inflammation in oligodendrocyte 
regeneration. J Neurosci 23:9824-9832. 
Bauer J, Sminia T, Wouterlood FG, Dijkstra CD (1994) Phagocytic activity of 
macrophages and microglial cells during the course of acute and chronic 
relapsing experimental autoimmune encephalomyelitis. J Neurosci Res 38:365-
375. 
Beyer M, Gimsa U, Eyüpoglu IY, Hailer NP, Nitsch R (2000) Phagocytosis of 
neuronal or glial debris by microglial cells: Upregulation of MHC class II 
expression and multinuclear giant cell formation in vitro. Glia 31:262-266. 
144 
Bjartmar C, Wujek JR, Trapp BD (2003) Axonal loss in the pathology of MS: 
consequences for understanding the progressive phase of the disease. J Neurol 
Sci 206:165-171. 
Bjartmar C, Yin X, Trapp BD (1999) Axonal pathology in myelin disorders. J 
Neurocytol 28:383-395. 
Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering 
the molecular mechanisms. Nat Rev Neurosci 8:57-69. 
Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, 
Aerts JM, Amor S, Nieuwenhuis EE, Laman JD (2006) Myelin-laden macrophages 
are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 
129:517-526. 
Bowman CC, Rasley A, Tranguch SL, Marriott I (2003) Cultured astrocytes express 
toll-like receptors for bacterial products. Glia 43:281-291. 
Bradl M, Linington C (1996) Animal models of demyelination. Brain Pathol 6:303-
311. 
Bridge KE, Berg N, Adalbert R, Babetto E, Dias T, Spillantini MG, Ribchester RR, 
Coleman MP (2007) Late onset distal axonal swelling in YFP-H transgenic mice. 
Neurobiol Aging. 
Brown A (2003) Axonal transport of membranous and nonmembranous cargoes: a 
unified perspective. J Cell Biol 160:817-821. 
Chang RC, Hudson PM, Wilson BC, Liu B, Abel H, Hong JS (2000) High 
concentrations of extracellular potassium enhance bacterial endotoxin 
lipopolysaccharide-induced neurotoxicity in glia-neuron mixed cultures. 
Neuroscience 97:757-764. 
Cleveland DW, Monteiro MJ, Wong PC, Gill SR, Gearhart JD, Hoffman PN (1991) 
Involvement of neurofilaments in the radial growth of axons. J Cell Sci 100 
Suppl. 15:85-95. 
 
145 
Comley LH, Wishart TM, Baxter B, Murray LM, Nimmo A, Thomson D, Parson SH, 
Gillingwater TH (2011) Induction of cell stress in neurons from transgenic mice 
expressing yellow fluorescent protein: implications for neurodegeneration 
research. PLoS ONE 6:e17639. 
De Stefano N, Matthews PM, Fu LQ, Narayanan S, Stanley J, Francis GS, Antel JP, 
Arnold DL (1998) Axonal damage correlates with disability in patients with 
relapsing-remitting multiple sclerosis - Results of a longitudinal magnetic 
resonance spectroscopy study. Brain 121:1469-1477. 
De Vos K, Severin F, Van Herreweghe F, Vancompernolle K, Goossens V, Hyman 
A, Grooten J (2000) Tumor necrosis factor induces hyperphosphorylation of 
kinesin light chain and inhibits kinesin-mediated transport of mitochondria. J 
Cell Biol 149:1207-1214. 
Domercq M, Sanchez-Gomez MV, Sherwin C, Etxebarria E, Fern R, Matute C 
(2007) System xc- and glutamate transporter inhibition mediates microglial 
toxicity to oligodendrocytes. J Immunol 178:6549-6556. 
Edgar JM, Anderson TJ, Dickinson PJ, Barrie JA, McCulloch MC, Nave K-A, 
Griffiths IR (2002) Survival of, and competition between, oligodendrocytes 
expressing different alleles of the Plp gene. J Cell Biol 158:719-729. 
Edgar JM, Griffiths IR (2009) Whiter Matter Structure: A Microscopist's View. In: 
Diffusion MRI (Johansen-Berg H, Behrens TEJ, eds), pp 75-103. London: Elsevier. 
Edgar JM, McCulloch MC, Montague P, Brown AM, Thilemann S, Pratola L, 
Gruenenfelder FI, Griffiths IR, Nave KA (2010) Demyelination and axonal 
preservation in a transgenic mouse model of Pelizaeus-Merzbacher disease. 
EMBO Mol Med 2:42-50. 
Edgar JM, McCulloch MC, Thileman S, Barrie JA, Nave K-A, Griffiths IR (2007) 
Axonal transport stasis correlates with inflammation in a demyelinating mouse 
model. pp 362. 
Edgar JM, McLaughlin M, McCulloch MC, Barrie JA, Nave K-A, Griffiths IR (2001) 
Proteolipid protein deficient myelin induces axonal swellings in shiverer mice. 
pp 103:11. 
146 
Edgar JM, Nave KA (2009) The role of CNS glia in preserving axon function. Curr 
Opin Neurobiol 19:498-504. 
Feng GP, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, 
Nerbonne JM, Lichtman JW, Sanes JR (2000) Imaging neuronal subsets in 
transgenic mice expressing multiple spectral variants of GFP. Neuron 28:41-51. 
Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute 
multiple sclerosis lesions. Brain 120:393-399. 
Friede RL, Samorajski T (1970) Axon caliber related to neurofilaments and 
microtubules in sciatic nerve fibers of rats and mice. Anat Rec 167:379-388. 
Garbern J, Yool DA, Moore GJ, Wilds I, Faulk M, Klugmann M, Nave K-A, 
Sistermans EA, van der Knaap MS, Bird TD, Shy ME, Kamholz J, Griffiths IR 
(2002a) Patients lacking the major CNS myelin protein, proteolipid protein 1, 
develop length-dependent axonal degeneration in the absence of demyelination 
and inflammation. Brain 125:551-561. 
Garbern JY, Yool DA, Moore GJ, Wilds IB, Faulk MW, Klugmann M, Nave KA, 
Sistermans EA, van der Knaap MS, Bird TD, Shy ME, Kamholz JA, Griffiths IR 
(2002b) Patients lacking the major CNS myelin protein, proteolipid protein 1, 
develop length-dependent axonal degeneration in the absence of demyelination 
and inflammation. Brain 125:551-561. 
Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D (2003) 
Axonal damage is reduced following glatiramer acetate treatment in C57/bl 
mice with chronic-induced experimental autoimmune encephalomyelitis. 
Neurosci Res 47:201-207. 
Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway 
SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M (2010) Fate mapping analysis 
reveals that adult microglia derive from primitive macrophages. Science 
330:841-845. 
Gitik M, Liraz-Zaltsman S, Oldenborg PA, Reichert F, Rotshenker S (2011) Myelin 
down-regulates myelin phagocytosis by microglia and macrophages through 
interactions between CD47 on myelin and SIRPalpha (signal regulatory protein-
alpha) on phagocytes. J Neuroinflammation 8:24. 
147 
Glim JE, Vereyken EJ, Heijnen DA, Vallejo JJ, Dijkstra CD (2010) The release of 
cytokines by macrophages is not affected by myelin ingestion. Glia 58:1928-
1936. 
Graf vK, Schramm U (1984) Diameter of axons and thickness of myelin sheaths of 
the pyramidal tract fibres in the adult human medullary pyramid. Anat Anz 
157:97-111. 
Griffiths IR, Klugmann M, Anderson TJ, Yool D, Thomson CE, Schwab MH, 
Schneider A, Zimmermann F, McCulloch MC, Nadon NL, Nave K-A (1998) Axonal 
swellings and degeneration in mice lacking the major proteolipid of myelin. 
Science 280:1610-1613. 
Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, Esterbauer 
H, Binder CJ, Witztum JL, Lassmann H (2011) Oxidative damage in multiple 
sclerosis lesions. Brain 134:1914-1924. 
Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector 
cells in the normal and pathologic brain. Nat Neurosci 10:1387-1394. 
Hendriks JJ, Teunissen CE, De Vries HE, Dijkstra CD (2005) Macrophages and 
neurodegeneration. Brain Res Brain Res Rev 48:185-195. 
Hikawa N, Takenaka T (1996) Myelin-stimulated macrophages release 
neurotrophic factors for adult dorsal root ganglion neurons in culture. Cell Mol 
Neurobiol 16:517-528. 
Hoffman PN, Griffin JW, Price DL (1984) Control of axonal caliber by 
neurofilament transport. J Cell Biol 99:705-714. 
Howe CL, Ure D, Adelson JD, LaFrance-Corey R, Johnson A, Rodriguez M (2007) 
CD8+ T cells directed against a viral peptide contribute to loss of motor function 
by disrupting axonal transport in a viral model of fulminant demyelination. J 
Neuroimmunol 188:13-21. 
Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ, Reynolds R (2010) 
Activated Microglia Mediate Axoglial Disruption That Contributes to Axonal Injury 
in Multiple Sclerosis. J Neuropathol Exp Neurol. 
148 
Ip CW, Kohl B, Kleinschnitz C, Reuss B, Nave KA, Kroner A, Martini R (2008) 
Origin of CD11b+ macrophage-like cells in the CNS of PLP-overexpressing mice: 
low influx of haematogenous macrophages and unchanged blood-brain-barrier in 
the optic nerve. Mol Cell Neurosci 38:489-494. 
Ip CW, Kroner A, Bendszus M, Leder C, Kobsar I, Fischer S, Wiendl H, Nave KA, 
Martini R (2006) Immune cells contribute to myelin degeneration and 
axonopathic changes in mice overexpressing proteolipid protein in 
oligodendrocytes. J Neurosci 26:8206-8216. 
Janeway C.A., Travers P, Walport M, Shlomchik MJ (2005) Immunology. In: 
immunology Garland Science. 
Jeon SB, Yoon HJ, Park SH, Kim IH, Park EJ (2008) Sulfatide, a major lipid 
component of myelin sheath, activates inflammatory responses as an 
endogenous stimulator in brain-resident immune cells. J Immunol 181:8077-
8087. 
Karim SA, Barrie JA, McCulloch MC, Montague P, Edgar JM, Kirkham D, Anderson 
TJ, Nave K-A, Griffiths IR, McLaughlin M (2007) PLP overexpression perturbs 
myelin protein composition and myelination in a mouse model of Pelizaeus-
Merzbacher disease. Glia 55:341-351. 
Kerschensteiner M, Meinl E, Hohlfeld R (2009) Neuro-immune crosstalk in CNS 
diseases. Neuroscience 158:1122-1132. 
Kerschensteiner M, Schwab ME, Lichtman JW, Misgeld T (2005) In vivo imaging of 
axonal degeneration and regeneration in the injured spinal cord. Nature Med 
11:572-577. 
Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R (2003) 
Neurotrophic cross-talk between the nervous and immune systems: implications 
for neurological diseases. Ann Neurol 53:292-304. 
Klugmann M, Schwab MH, Jung M, Pühlhofer A, Schneider A, Zimmermann F, 
Griffiths IR, Nave K-A (1997a) Mutations of the X-linked proteolipid protein gene: 
molecular mechanisms of dysmyelination. In: Cell Biology and Pathology of 
Myelin:Evolving Biological Concepts and Therapeautic Approaches (Devon RM, 
149 
Doucette JR, Juurlink BHJ, Schreyer DJ, Verge VMK, eds), New York: Plenum 
Press. 
Klugmann M, Schwab MH, Pühlhofer A, Schneider A, Zimmermann F, Griffiths IR, 
Nave K-A (1997b) Assembly of CNS myelin in the absence of proteolipid protein. 
Neuron 18:59-70. 
Kotter MR, Zhao C, van RN, Franklin RJ (2005) Macrophage-depletion induced 
impairment of experimental CNS remyelination is associated with a reduced 
oligodendrocyte progenitor cell response and altered growth factor expression. 
Neurobiol Dis 18:166-175. 
Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution 
and morphology of microglia in the normal adult mouse brain. Neuroscience 
39:151-170. 
Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, 
Vartanian T (2003) Activation of innate immunity in the CNS triggers 
neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl 
Acad Sci U S A 100:8514-8519. 
Lindner M, Fokuhl J, Linsmeier F, Trebst C, Stangel M (2009) Chronic toxic 
demyelination in the central nervous system leads to axonal damage despite 
remyelination. Neurosci Lett 453:120-125. 
Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of 
demyelination in rat acute allergic encephalomyelitis by circulating mouse 
monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. 
Am J Path 130:443-454. 
Liu Y, Hao W, Letiembre M, Walter S, Kulanga M, Neumann H, Fassbender K 
(2006) Suppression of microglial inflammatory activity by myelin phagocytosis: 
role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 
26:12904-12913. 
Lunnon K, Teeling JL, Tutt AL, Cragg MS, Glennie MJ, Perry VH (2011) Systemic 
inflammation modulates Fc receptor expression on microglia during chronic 
neurodegeneration. J Immunol 186:7215-7224. 
150 
Magnus T, Chan A, Grauer O, Toyka KV, Gold R (2001) Microglial phagocytosis of 
apoptotic inflammatory T cells leads to down-regulation of microglial immune 
activation. J Immunol 167:5004-5010. 
Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to 
study demyelination and remyelination in the central nervous system. Brain 
Pathol 11:107-116. 
McArthur S, Cristante E, Paterno M, Christian H, Roncaroli F, Gillies GE, Solito E 
(2010) Annexin A1: a central player in the anti-inflammatory and 
neuroprotective role of microglia. J Immunol 185:6317-6328. 
Medana I, Martinic MA, Wekerle H, Neumann H (2001) Transection of major 
histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. 
Am J Pathol 159:809-815. 
Morris RL, Hollenbeck PJ (1993) The regulation of bidirectional mitochondrial 
transport is coordinated with axonal outgrowth. J Cell Sci 104:917-927. 
Mosley K, Cuzner ML (1996) Receptor-mediated phagocytosis of myelin by 
macrophages and microglia: effect of opsonization and receptor blocking agents. 
Neurochem Res 21:481-487. 
Nakamura Y, Si QS, Kataoka K (1999) Lipopolysaccharide-induced microglial 
activation in culture: temporal profiles of morphological change and release of 
cytokines and nitric oxide. Neurosci Res 35:95-100. 
Napoli I, Neumann H (2009) Microglial clearance function in health and disease. 
Neuroscience 158:1030-1038. 
Nash B, Thomson CE, Linington C, Arthur AT, McClure JD, McBride MW, Barnett 
SC (2011) Functional duality of astrocytes in myelination. J Neurosci 31:13028-
13038. 
Nave KA (2010) Myelination and the trophic support of long axons. Nat Rev 
Neurosci 11:275-283. 
Neumann H, Kotter MR, Franklin RJ (2009) Debris clearance by microglia: an 
essential link between degeneration and regeneration. Brain 132:288-295. 
151 
Neumann J, Sauerzweig S, Ronicke R, Gunzer F, Dinkel K, Ullrich O, Gunzer M, 
Reymann KG (2008) Microglia cells protect neurons by direct engulfment of 
invading neutrophil granulocytes: a new mechanism of CNS immune privilege. J 
Neurosci 28:5965-5975. 
Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, Bruck 
W, Bishop D, Misgeld T, Kerschensteiner M (2011) A reversible form of axon 
damage in experimental autoimmune encephalomyelitis and multiple sclerosis. 
Nat Med 17:495-499. 
Nikodemova M, Lee J, Fabry Z, Duncan ID (2010) Minocycline attenuates 
experimental autoimmune encephalomyelitis in rats by reducing T cell 
infiltration into the spinal cord. J Neuroimmunol 219:33-37. 
Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly 
dynamic surveillants of brain parenchyma in vivo. Science 308:1314-1318. 
Norton WT, Poduslo SE (1973) Myelination in the rat brain: method of myelin 
isolation. J Neurochem 21:749-757. 
Ovanesov MV, Ayhan Y, Wolbert C, Moldovan K, Sauder C, Pletnikov MV (2008) 
Astrocytes play a key role in activation of microglia by persistent Borna disease 
virus infection. J Neuroinflammation 5:50. 
Palin K, Cunningham C, Forse P, Perry VH, Platt N (2008) Systemic inflammation 
switches the inflammatory cytokine profile in CNS Wallerian degeneration. 
Neurobiol Dis 30:19-29. 
Pang Y, Campbell L, Zheng B, Fan L, Cai Z, Rhodes P (2010) Lipopolysaccharide-
activated microglia induce death of oligodendrocyte progenitor cells and impede 
their development. Neuroscience 166:464-475. 
Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987) Treatment of multiple 
sclerosis with gamma interferon: exacerbations associated with activation of the 
immune system. Neur 37:1097-1102. 
Peri F, Nusslein-Volhard C (2008) Live imaging of neuronal degradation by 
microglia reveals a role for v0-ATPase a1 in phagosomal fusion in vivo. Cell 
133:916-927. 
152 
Perry VH (1994) Functions of microglia. In: Macrophages and the nervous system 
(Perry VH, ed), pp 44-52. Austin: R.G. Landes. 
Perry VH (2010) Contribution of systemic inflammation to chronic 
neurodegeneration. Acta Neuropathol 120:277-286. 
Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat 
Rev Neurol 6:193-201. 
Pohl HB, Porcheri C, Mueggler T, Bachmann LC, Martino G, Riethmacher D, 
Franklin RJ, Rudin M, Suter U (2011) Genetically induced adult oligodendrocyte 
cell death is associated with poor myelin clearance, reduced remyelination, and 
axonal damage. J Neurosci 31:1069-1080. 
Polazzi E, Monti B (2010) Microglia and neuroprotection: from in vitro studies to 
therapeutic applications. Prog Neurobiol. 
Popovich PG, Longbrake EE (2008) Can the immune system be harnessed to 
repair the CNS? Nat Rev Neurosci 9:481-493. 
Prinz M, Priller J, Sisodia SS, Ransohoff RM (2011) Heterogeneity of CNS myeloid 
cells and their roles in neurodegeneration. Nat Neurosci 14:1227-1235. 
Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized 
responses. Annu Rev Immunol 27:119-145. 
Rasmussen S, Wang Y, Kivisakk P, Bronson RT, Meyer M, Imitola J, Khoury SJ 
(2007) Persistent activation of microglia is associated with neuronal dysfunction 
of callosal projecting pathways and multiple sclerosis-like lesions in relapsing--
remitting experimental autoimmune encephalomyelitis. Brain 130:2816-2829. 
Readhead C, Schneider A, Griffiths IR, Nave K-A (1994) Premature arrest of 
myelin formation in transgenic mice with increased proteolipid protein gene 
dosage. Neuron 12:583-595. 
Renault-Mihara F, Okada S, Shibata S, Nakamura M, Toyama Y, Okano H (2008) 
Spinal cord injury: emerging beneficial role of reactive astrocytes' migration. Int 
J Biochem Cell Biol 40:1649-1653. 
153 
Rigato C, Buckinx R, Le Corronc H, Rigo JM, Legendre P (2011) Pattern of 
invasion of the embryonic mouse spinal cord by microglial cells at the time of 
the onset of functional neuronal networks. Glia 59:675-695. 
Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR, Peterson PK 
(2004) Role of microglia in central nervous system infections. Clin Microbiol Rev 
17:942-64, table. 
Satoh J, Kuroda Y (2001) Differing effects of IFN beta vs IFN gamma in MS: gene 
expression in cultured astrocytes. Neur 57:681-685. 
Schenk D, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-
disease-like pathology in the PDAPP mouse. Nature 400:173-177. 
Schwartz M, Butovsky O, Bruck W, Hanisch UK (2006) Microglial phenotype: is the 
commitment reversible? Trends Neurosci 29:68-74. 
Shy ME, Hobson G, Jain M, Boespflug-Tanguy O, Garbern J, Sperle K, Li W, Gow 
A, Rodriguez D, Bertini E, Mancias P, Krajewski K, Lewis R, Kamholz J (2003) 
Schwann cell expression of PLP1 but not DM20 is necessary to prevent 
neuropathy. Ann Neurol 53:354-365. 
Skripuletz T, Bussmann JH, Gudi V, Koutsoudaki PN, Pul R, Moharregh-Khiabani 
D, Lindner M, Stangel M (2010) Cerebellar cortical demyelination in the murine 
cuprizone model. Brain Pathol 20:301-312. 
Smith KJ, Kapoor R, Hall SM, Davies M (2001) Electrically active axons 
degenerate when exposed to nitric oxide. Ann Neurol 49:470-476. 
Sobottka B, Harrer MD, Ziegler U, Fischer K, Wiendl H, Hunig T, Becher B, 
Goebels N (2009) Collateral bystander damage by myelin-directed CD8+ T cells 
causes axonal loss. Am J Pathol 175:1160-1166. 
Stagi M, Dittrich PS, Frank N, Iliev AI, Schwille P, Neumann H (2005) Breakdown 
of axonal synaptic vesicle precursor transport by microglial nitric oxide. J 
Neurosci 25:352-362. 
154 
Stagi M, Gorlovoy P, Larionov S, Takahashi K, Neumann H (2006) Unloading 
kinesin transported cargoes from the tubulin track via the inflammatory c-Jun N-
terminal kinase pathway. FASEB J 20:2573-2575. 
Sun X, Wang X, Chen T, Li T, Cao K, Lu A, Chen Y, Sun D, Luo J, Fan J, Young W, 
Ren Y (2010) Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-
dependent inflammatory response in murine system. PLoS One 5:e9380. 
Thomson CE, McCulloch M, Sorenson A, Barnett SC, Seed BV, Griffiths IR, 
McLaughlin M (2008) Myelinated, synapsing cultures of murine spinal cord--
validation as an in vitro model of the central nervous system. Eur J Neurosci 
28:1518-1535. 
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998a) Axonal 
transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285. 
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L (1998b) Axonal 
transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285. 
Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, Baggiolini M (1995) Actions of 
the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 
beta on human monocytes. Eur J Immunol 25:64-68. 
van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Dopp EA, Dijkstra CD (1996) 
Macrophage phagocytosis of myelin in vitro determined by flow cytometry: 
phagocytosis is mediated by CR3 and induces production of tumor necrosis 
factor-alpha and nitric oxide. J Neuroimmunol 70:145-152. 
van ZM, Wierenga-Wolf AF, Melief MJ, Schrijver B, Laman JD, Boven LA (2010) 
Myelin ingestion by macrophages promotes their motility and capacity to recruit 
myeloid cells. J Neuroimmunol 225:112-117. 
Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J (2009) Resting microglia 
directly monitor the functional state of synapses in vivo and determine the fate 
of ischemic terminals. J Neurosci 29:3974-3980. 
Walter L, Neumann H (2009) Role of microglia in neuronal degeneration and 
regeneration. Semin Immunopathol 31:513-525. 
155 
Williams K, Ulvestad E, Waage A, Antel JP, McLaurin J (1994) Activation of adult 
human derived microglia by myelin phagocytosis in vitro. J Neurosci Res 38:433-
443. 
Yool DA, Edgar JM, Montague P, Malcolm S (2000) The proteolipid protein gene 
and myelin disorders in man and animal models. Hum Mol Genet 9:987-992. 
Zhang SC, Goetz BD, Carré JL, Duncan ID (2001) Reactive microglia in 
dysmyelination and demyelination. Glia 34:101-109. 
Zhang SC, Goetz BD, Duncan ID (2003) Suppression of activated microglia 
promotes survival and function of transplanted oligodendroglial progenitors. Glia 
41:191-198. 
 
 
